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ABSTRACT 
 
 
The purpose of this study is to detect chromosomal loci predisposing to autism spectrum 
disorders in the Finnish population. Families were collected and recruited through a 
nationwide collaborative project. Due to the rarity of autism and the small size of the Finnish 
population a wide phenotype was accepted including families with two or more affected 
individuals with autism, Asperger syndrome (AS) and/or developmental dysphasia. 
  
This thesis consists of the molecular genetic studies on autism spectrum of disorders in 
Finland. We initiated the study by investigating the previously reported susceptibility regions 
with 17 families with autism and AS. In study I, we reported the findings for 10 chromosomal 
regions studied. Of these only the region on chromosome 1q showed slight evidence for 
linkage. 
 
Most genome-wide reports on autism have been performed with mixed family material 
mainly from Caucasian populations. Taking into account the population history of Finland, 
we postulated that Finns may harbour novel susceptibility genes for autism. In study II, we 
report genome-wide linkage findings with 38 families with autism, AS and dysphasia. For 
analysis purposes we divided the material into three diagnostic criteria: (1) patients with 
autism, (2) patients with autism and AS and (3) patients with autism, AS and developmental 
dysphasia. The maximum multipoint lod score (MLS) of 4.81 was obtained on chromosome 
3q25-27 in families with autism and AS. This locus was designated as AUTS2. This is a 
novel locus that needs to be analysed in other populations to confirm whether it is a rare locus 
unique to the Finns. Other regions with lod scores over 2 were detected on chromosomes 1 
and 7, both overlapping with the results obtained from other populations. Association 
analyses supported the linkage finding on chromosome 1 in patients with autism. 
 
Genealogical studies were performed in order to search for a possible founder effect in 
autism. In fact, 51% of the grandparents of the patients in the genome scan were shown to 
originate from late settlement region of Central Finland. In study III, 31 families originating 
from this particular region were analysed. Evidence for the extended region showing an 
association was obtained on chromosome 3q suggesting that this region may act as a major 
predisposing locus for autism in this subisolate. 
 
During this thesis, the methyl-CpG binding protein 2 (MECP2) gene was identified to 
underlie Rett syndrome, a member of the autism spectrum disorders (Amir et al. 1999). In 
study IV, we screened 52 patients with Rett syndrome (RTT) for mutations in this gene. We 
found a disease-causing mutation in 39/39 of the classical patients and in one patient with 
preserved speech variant (PSV). A novel mutation, P127L, was detected in a patient with 
PSV in the MECP2 coding region. We also analysed a total of 12 atypical RTT patients, and 
no mutations were found in the MECP2 gene. The mutation spectrum of the Finnish patients 
did not differ from that of the non-Finnish patients. Our studies also included X chromosome 
inactivation analyses. No clear correlation was detected between the phenotype and/or X-
inactivation status and the type of the mutation, which is in line with the previously published 
reports.  
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INTRODUCTION 
 
 
The autism spectrum of disorders are severe developmental disorders of childhood that affect 
about 1% of populations worldwide (Folstein and Rosen-Sheidley 2001). The disease group 
consist of several diseases with varying severity, including classical autism, Asperger 
syndrome (AS), atypical autism, childhood disintegrative disorder and Rett syndrome (RTT). 
Characteristic features include abnormalities in social interaction and communication as well 
as repetitive and stereotypic behaviour.  Classical autism is typically recognised before the 
age of three years whereas in AS the fully blown phenotype can be detected at the age of 5-8 
(Gillberg 1998a). In AS, difficulties in social communication predominate while the 
development of the language and intelligence are normal. RTT, inherited as an X-linked 
dominant trait affects girls, who after normal development manifest in addition to autistic 
features deceleration of head growth, loss of acquired hand skills and language, and 
stereotypic hand movements (Hagberg 1993b).  
 
Developmental dysphasia is a severe language disorder that affects about 5-10% of 
preschoolers (Tomblin et al. 1997; Rapin 1998). It is distinguished from autism by the 
absence of social or behavioural abnormalities. An association of this disorder with autism 
has been suggested, e.g. since the family members of autistic probands often possess milder 
disease traits similar to autism (Folstein and Mankoski 2000).  
  
The etiology of autism spectrum of disorders is unknown. The genetic component of autism 
was confirmed by the first twin study in 1977 showing significantly higher concordance rates 
for monozygotic than for dizygotic twins (Folstein and Rutter 1977).  Current estimates for 
the recurrence risk of autism in the siblings is ~3%, and the heritability estimate is over 90% 
(Folstein and Rosen-Sheidley 2001). Clearly, autism is among the multifactorial disorders 
with a strong genetic component. 
 
The development of laboratory protocols and methods in the field of molecular genetics have 
facilitated the identification of genetic factors underlying multifactorial disorders including 
autism spectrum disorders. The candidate gene approach including the genes involved in the 
metabolic pathway of the neurotransmitter serotonin did not show supporting results, and 
studies to explore the whole genome were initiated. The first genome screen was published in 
1998 (IMGSAC 1998), and since then a total of eight genome-wide screens have been 
reported. Potential susceptibility loci for autism (lod score >1) have been detected in nearly 
every chromosome reflecting the difficulty in mapping major disease gene(s), and the 
heterogeneity between populations under study. A couple of loci, chromosome 7q 
susceptibility region (AUTS1), chromosome 1q and chromosome 2q, have been replicated in 
two or more studies (IMGSAC 1998; Barrett et al. 1999; Philippe et al. 1999; Risch et al. 
1999; IMGSAC 2001b; Buxbaum et al. 2001; Liu et al. 2001; Shao et al. 2002b). 
 
The first gene underlying the autism spectrum of disorders was detected in October 1999. It is 
the methyl-CpG-binding protein 2 (MECP2) gene that causes RTT (Amir et al. 1999). The 
protein product of this gene acts in the process of chromosome modification and gene 
silencing. So far mutations have been identified in ~80% of cases, and also in patients with 
nonspecific mental retardation (Meloni et al. 2000; Orrico et al. 2000; Couvert et al. 2001) 
and atypical Angelman syndrome (Imessaoudene et al. 2001; Watson et al. 2001).   
Molecular genetic analyses in autism spectrum disorders have not to date been performed in 
founder populations. This study is the first attempt to identify predisposing gene loci for 
autism spectrum disorders in the isolated Finnish population. Also the mutation spectrum of 
the MECP2 gene in Finnish Rett syndrome patients was analysed.  
10 
 
 
 
REVIEW OF THE LITERATURE 
 
 
1. AUTISM SPECTRUM DISORDERS AND DEVELOPMENTAL 
DYSPHASIA 
 
1.1. HISTORY 
 
The word ‘autism’ is derived from a Greek word ‘autos’ meaning the ‘self’. The term was 
first used as a description for individuals that become absorbed in their own world and lost 
contact with other people. The first clinician to use the word ‘autism’ was a Swiss 
psychiatrist Eugen Bleuler (1857-1939) in 1916 to describe the desire of schizophrenic (in 
Greek: schizen = to divide, phren = the mind) patients to withdraw from public places. The 
nosological status between autism and schizophrenia remained controversial for a long time. 
Autistic disorders were first introduced under the diagnostic criterion of childhood 
schizophrenia in the Diagnostic and Statistical Manual of Mental Disorders (DSM-II) 
(American Psychiatric Association, 1968).  
 
The original work of an American psychiatrist Leo Kanner in 1943 was the basis for the 
modern definition and today’s diagnostic criteria for infantile autism (Kanner 1943). He 
provided a detailed analysis of 11 children reported to possess ‘autistic disturbances of 
affective contact’. Because of the early onset abnormalities observed in most children’s 
behaviour, Kanner suggested the presence of an inborn, presumably genetic, disorder of 
affective contact (Kanner 1943). Later on Kanner noted that early cold relations between the 
parents and the affected children might be the root for autism. This led to speculations that 
problems in parent-child relationship could cause autism, an idea, which was later 
scientifically discarded. However, among lay people this belief was deeply rooted and the 
mothers of autistic children were especially blamed. 
 
To specify the diagnostic criteria for autism as a separate syndrome and to make a distinction 
between other similar conditions Rutter reported criteria for the diagnosis of infantile autism  
(Rutter 1978). A year later in 1979 Lorna Wing delineated the diagnostic criteria for a group 
of children with autism and autistic-like condition (Wing and Gould 1979), and also pointed 
out the following triad of abnormalities: in socialisation, in social communication, and in 
social play. In the subsequent classification system, DSM-III, of the American Psychiatric 
Association (APA) a similar triad of symptoms was formulated to belong to pervasive 
developmental disorders (PDD) including autism, childhood-onset PDD, residual autism and 
atypical autism in 1980. In the revised version of the criteria (DSM-III-R) the diagnostic 
categories of autism were widened and the concept of ‘pervasive developmental disorder not 
otherwise specified’ (PDD-NOS) was introduced to contain other forms of PDD.  
 
Shortly after Kanner’s publication in 1944, an Austrian paediatrician Hans Asperger 
described four boys with normal cognitive and verbal skills, who showed marked difficulties 
in social interaction, unusual circumscribed interests and motor difficulties. He suggested that 
this condition almost never becomes evident before three years of age, and that similar traits 
can be observed in the relatives of the probands, particularly in the males. 
  
It was not until the first English report by Wing appeared in 1981, that knowledge of the 
condition described by Asperger began to expand (Wing 1981). She widened the original 
diagnostic criteria by including the abnormal development of language or communication 
skills, mild mental retardation and female cases. The term Asperger syndrome (AS) was first 
inaccurately used, most commonly referred to as PDD-NOS. Detailed cross-sectional studies 
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defined the disease to belong to the PDD spectrum disorders (Gillberg 1989; Szatmari et al. 
1989; Szatmari 1992; Klin et al. 1995). The new diagnostic definitions were outlined in the 
DSM-IV in 1994 and in the international classification of diseases (ICD-10) (World Health 
Organization 1993), deliberately made identical. 
 
Developmental dysphasia belongs to diagnostic class of developmental language disorders 
(DLD), and is diagnosed in children that have early onset problems in language ability, but 
otherwise develop normally. The children have normal nonverbal IQs, no clearly identifiable 
neurological problems, no disabilities in hearing or articulation that would interfere with 
normal language acquisition (Ingram 1959; Rapin 1996). Cognitive deficit and a pervasive 
language disorder encompassing communication in general has been found to be an essential 
part of the syndrome of autism (Ferrari 1982; Bishop 1989; Tanguay et al. 1998) 
Comparative studies of clinical differences in groups of children with autism and 
developmental language disorders have been performed. It has been found that a distinction 
between these entities can clearly be made based on behavioural, language or cognitive 
features (Bartak et al. 1977). Interestingly, in a follow-up analysis of the Bartak sample the 
clinical outcome of the two patient groups was qualitatively found to be very similar (Howlin 
et al. 2000; Mawhood et al. 2000).  
 
 
1.2. CLINICAL CHARACTERISTICS AND CLASSIFICATION 
 
1.2.1. Infantile autism 
 
The diagnostic criteria of classical autism are shown in Table 1. In addition, mental 
retardation (MR) is present in 40-75% (Rutter 1979) and epilepsy in 25-30% of cases 
(Volkmar and Nelson 1990). Only about 10% of individuals with autism are able to live and 
function relatively independently (Lainhart and Piven 1995), and most require lifelong 
assistance. The two strongest predictions of the clinical outcome later on are the IQ and the 
level of language development at the age of five years (Bailey et al. 1996). 
 
Individuals with a diagnosis of autism have a recognisable medical syndrome in  ~10-15% of 
the cases (Folstein and Rosen-Sheidley 2001). These known medical conditions include e.g. 
phenylketonuria, Fragile-X syndrome, tuberculosis sclerosis, neurofibromatosis 1, Rett 
syndrome, Down syndrome, Angelman’s syndrome, cerebral palsy, Moebius syndrome and 
Cornelia de Lange’s syndrome. Environmental factors reported to cause autism are infectious 
diseases occurring prenatally or after birth (rubella, herpes simplex virus encephalitis) and 
some toxic syndromes (fetal alcohol syndrome, fetal cocaine or valproate exposure, lead 
poisoning and thalidomide embryopathy). 
 
The differential diagnosis of autism include e.g. other forms of PDD, developmental 
language disorders, mental retardation and deafness (Smalley et al. 1992; Rutter et al. 1994).   
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 Table 1. 
  
 
DIAGNOSTIC CRITERIA FOR AUTISM DISORDER (ICD-10) (WHO 1993) 
 
 
A. A total of six (or more) items from 1,2 and 3 with at least two from 1, and one 
each from 2 and 3:    
 
1. Qualitative impairment in social interaction, as manifested by at least two of the   
following: 
    a. marked impairment in the use of multiple non-verbal behaviours, such as eye-to-eye 
        gaze, facial expression, body postures, and gestures to regulate social interaction 
    b. failure to develop peer relationships appropriate to developmental level 
    c. a lack of spontaneous seeking to share enjoyment, interests, or achievements with 
        other people (e.g. by a lack of showing, bringing, or pointing out objects of interest) 
    d. lack of social or emotional reciprocity 
 
2. Qualitative impairment in communication as manifested by at least one of the 
following:        
    a. a delay in, or total lack of, the development of spoken language (not accompanied by 
        an attempt to compensate through alternative models of communication such as  
        gesture or mime) 
    b. in individuals with adequate speech, marked impairment in the ability to initiate or 
        sustain a conversation with others 
    c. stereotyped and repetitive use of language or idiosyncratic language 
    d. lack of varied, spontaneous make-believe play, or social imitative play, appropriate 
        to developmental level 
 
3. Restricted repetitive and stereotyped patterns of behaviour, interests and activities, as 
manifested by at least one of the following: 
    a. encompassing preoccupation with one or more stereotyped and restricted patterns of  
       interest, which is abnormal either in intensity or focus 
    b. apparently inflexible adherence to specific, non-functional routines or rituals 
    c. stereotyped and repetitive motor mannerisms (e.g. hand- or finger-flapping or  
       -twisting, or complex whole-body movements) 
    d. persistent preoccupation with parts of objects 
 
B. Delays or abnormal functioning in at least one of the following areas, with onset 
prior to age 3 years: 
    1. Social interaction. 
    2. Language as used in social communication 
    3. Symbolic or imaginative play. 
 
C. The disturbance is not better accounted for by Rett’s disorder or childhood 
disintegrative disorder. 
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1.2.2. Asperger Syndrome 
 
The different diagnostic criteria of AS currently in use are shown in Table 3. AS can be 
distinguished from autism and PDD-NOS on the basis of higher verbal IQs, higher rates of 
the disorder in the first degree relatives and different patterns of co-morbidity, especially 
depression (Volkmar et al. 2000).  
 
Recently, a novel multidimensional system to classify autism spectrum disorders has been 
proposed (Szatmari 2000) that emphasises the developmental process of the disease. The key 
factor in this process is the timing of the development of fluent language that will canalise the 
further development to a certain level of functioning. PDD subtypes might be classified as 
different developmental pathways that differentiate at certain time points, rather than separate 
entities. This means that the diagnostic criteria need not be changed, but focus should be 
emphasised on the genetic, epigenetic and environmental factors that move the child from 
one PDD pathway to another. 
 
1.2.3. Developmental dysphasia 
 
Under ICD-10 criteria the disorder is classified either as expressive type of language disorder 
(F80.1) or mixed receptive-expressive type of language disorder (F80.2) (World Health 
Organization 1993). The diagnostic criteria are shown in Table 2. 
 
 
Table 2. 
DIAGNOSTIC CRITERIA FOR DEVELOMENTAL LANGUAGE DISORDERS 
(ICD-10) (WHO 1993) 
 
EXPRESSIVE LANGUAGE DISORDER (F80.1) 
A. Symptoms including markedly limited vocabulary, making errors in tense, having 
difficulties in recalling words or producing sentences with developmentally 
appropriate length or complexity 
B. The difficulties with expressive language interfere with academic or occupational 
achievement or with social communication. 
C. Criteria are not met for mixed Receptive-expressive language disorder or for PDD 
D. If mental retardation, a speech-motor or sensory deficit, or environmental deprivation 
is present, the language difficulties are in excess of those usually associated with 
these problems. 
 
MIXED RECEPTIVE-EXPRESSIVE LANGUAGE DISORDER (F80.2) 
A. Symptoms include those for Expressive language disorder as well as difficulties in 
understanding words, sentences, or specific types of words such as spatial terms. 
B. The difficulties with mixed receptive-expressive language interfere with academic or 
occupational achievement or with social communication. 
C. Criteria are not met for PDD.  
D. If mental retardation, a speech-motor or sensory deficit, or environmental deprivation 
is present, the language difficulties are in excess of those usually associated with 
these problems. 
   
14 
 
 
   Table 3. The clinical criteria for AS.  
CLINICAL FEATURE ASPERGER (1944; 1979) WING 1981 
GILLBERG & 
GILLBERG 
(1989) 
TANTUM 
(1988) 
SZATMARI 
(1989) 
ICD-10 
(WHO, 1993) 
DSM-IV 
(APA, 1994) 
        
Social impairment Yes Yes      Yes Yes Yes Yes Yes
Poor nonverbal communication Yes      Yes Yes Yes Yes Yes Yes 
Poor empathy Yes      Yes Yes Yes Yes Yes Yes 
Failure to develop friendships Yes     Yes Yes Yes (implied) Yes Yes Yes 
        
Language/ 
Communication 
       
Poor prosody and pragmatics Yes     Yes Yes Yes Yes Not stated Not stated 
Idiosyncratic language Yes  Yes Not stated Not stated Yes Not stated Not stated 
Impoverished imaginative play Yes Yes Not stated Not stated Not stated Yes Not stated 
        
All-absorbing interest Yes    Yes Yes Yes Not stated Yes Often 
        
Motor clumsiness     Yes Yes Yes Yes Not stated Yes (common) Often 
        
Onset (0-3 years)        
Speech delays/ 
Deviance 
No May be present May be 
present 
Not stated Not stated No No 
Cognitive delays No May be present Not stated Not stated Not stated No No 
Motor delays Yes Sometimes Not stated Not stated Not stated May be 
present 
May be 
present 
Exclusion of autism Yes (1979) No      No No Yes Yes Yes
        
Mental retardation No May be present Not stated Not stated Not stated Not stated Not stated 
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      Table adapted from Volkmar and Klin, 2001
 
 
1.3. EPIDEMIOLOGICAL STUDIES 
 
 
Prior to 1988, the surveys conducted on children and adolescents estimated the prevalence of 
autism to be 4-5 per 10 000, and the prevalence of any of the PDD phenotypes 19 per 10 000 
(Fombonne 1999). However, the latest epidemiological studies have reported increased 
prevalence rates for this group of disorders.  In the Japanese population a prevalence rate of 
21 per 10 000 has been found for autism among children at the age of five (Honda et al. 
1996). In a recent study performed on autism in Northern Finland, similar figures were 
reported. The cumulative incidence was found to be highest, 20.7 per 10 000, in the age 
group of 5-7 year-olds and lowest, 6.1 per 10 000, in the age group of 15- to 18-year-old 
children, when the criteria of the ICD-10 and the DSM-IV were used (Kielinen et al. 2000), 
whereas in the United Kingdom a prevalence rate of 16.8 per 10 000 and 63 per 10 000 have 
been found for autism and PDD respectively in children younger than five years of age 
(Chakrabarti and Fombonne 2001).  
 
So far, three Swedish epidemiological studies have been performed on AS, the first of which 
conducted on 7 year old children reported a prevalence of 28.5 per 10 000 for cases fulfilling 
ICD-10 criteria (Gillberg and Gillberg 1989). In a cohort of 7- to 16-year-olds, the prevalence 
of 35.7 per 10 000 was obtained for AS fulfilling the author’s own criteria (Ehlers and 
Gillberg 1993). The recent Swedish study reported a rate of 48 per 10 000 in 7- to 11-year 
olds (Kadesjo and Gillberg 1999). The variation between these studies might be explained by 
methodological issues and the ages of the study groups.  
 
Autism is more common in males with the average male to female ratio of four to one (Bailey 
et al. 1995; Fombonne 1999). Twin studies on autism show elevated concordance rates for 
monozygotic twins (MZ) (36-95%) compared to dizygotic twins (DZ) (0-23%) (Folstein and 
Rutter 1977; Steffenburg et al. 1989; Bailey et al. 1995). Also, in an article of 166 affected 
sib pairs, an excess of twins was reported (12 MZ, 17 DZ and 1 unknown zygosity), which 
deviated from the expected values significantly (P<10-6). The authors speculate that parental 
risk factors, either related to twinning or fetal development or other risk factors (genetic or 
environmental) may contribute to autism (Greenberg et al. 2001). Another study also found 
an excess of twins in a sample of 79 affected sib-pairs, however in their sample only MZ 
twins were over represented (Betancur et al. 2002).  The data from a recent report with 465 
patients from Western Australia strongly suggests that twinning itself is not a risk factor for 
autism. They demonstrate that the high proportion of twins can be explained by the high ratio 
of concordance rates in MZ twins versus siblings and the distribution of family size in the 
population studied (Hallmayer et al. 2002). 
 
The data from the family and twin studies suggests that the phenotypic spectrum of autistic 
traits is broader than originally thought (Bolton et al. 1994; Bailey et al. 1998b). Family 
studies have estimated the recurrence rate of autism among siblings to be ~3-6% (Smalley 
1997). Considering the recurrence risk for a broad phenotype including language-related 
cognitive disorders and/or deficits of social functioning some studies show an increased risk 
(between 12.4 and 20.4%) depending on the inclusion criteria (Bolton et al. 1994; Piven et al. 
1997a). In most studies marked abnormalities in social behaviour are observed in the 
minority of the first-degree relatives of autistic probands, but milder abnormalities are seen in 
a large proportion (Bailey et al. 1998b). In the combined analysis of all published family 
studies cited above, the risk for autism in second-degree relatives is 0.18% and in third-
degree relatives 0.12% (Szatmari et al. 1998). Given a family with more than two affected 
children, the recurrence risk might be as high as 25% (Folstein and Rosen-Sheidley 2001). 
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For developmental language disorders, an overall prevalence rate of 7.4% was found among 
monolingual English-speaking kindergarten children (Tomblin et al. 1997). Twin and family 
studies performed on DLD have reported concordance rates of 70% and 45% for MZ and DZ 
twins respectively (Lewis and Thompson 1992; Bishop et al. 1995; Tomblin and Buckwalter 
1998). It has been proposed that the disorder has a biological basis, and is not only a 
consequence of abnormal social functioning (Rapin and Dunn 1997). Although autism 
spectrum disorders and DLD are classified as distinctive disorders, some evidence for an 
association between these entities has accumulated. An increased risk of language-related 
problems (articulation, pragmatic, spelling and reading difficulties) have been observed in the 
first-degree relatives of autistic individuals (Landa et al. 1992), as well as delay in the 
language development (Bailey et al. 1995).  
 
A long-term follow-up study of two male groups, one with autism and the other with 
developmental receptive language disorder reported some degree of clinical overlap between 
the groups (Howlin et al. 2000; Mawhood et al. 2000). The significant problems observed in 
the autism group, abnormalities in stereotyped behavioural patterns and social relationships 
were also present in the language group. A total of 65% had moderate social problems and 
25% were rated as being near/completely normal in social functioning. The two groups were 
first assessed in early childhood, when aged 7 to 8, and the study was completed when the 
participants were aged, on average, 23 to 24. These findings suggest that there are common 
traits in these disorders. The traits are more easily recognisable during childhood whereas in 
the adulthood though the abnormalities in language development are qualitatively similar, 
only the magnitude of the impairments is different. The boundaries of these two disorders are 
still to be characterised. 
 
 
1.4. NEUROPATHOLOGICAL, BRAIN IMAGING AND METABOLIC STUDIES 
 
 
In the neuropathological studies, no gross structural abnormalities have been reported. 
Interestingly, a recent report performed in nine patients with autism suggests that the 
minicoluns, consisting of neurons in layers VI to II of the brain, are significantly smaller and 
less compact in patients with autism (Casanova et al. 2002). Some studies have shown 
reduced Purkinje cell densities in the cerebellum, a diminished number of neurons in the 
cerebellar granule cell layer and cellular abnormalities in the areas of the limbic system 
(Bauman and Kemper 1985; Kemper and Bauman 1998). In a study by Bailey et al. the brains 
of six mentally handicapped patients with autism were analysed. Four of the subjects 
presented cortical developmental abnormalities, suggesting the involvement of cerebral 
cortex in autism (Bailey et al. 1998a).  
 
In a recent neuroanatomical study of MZ twins discordant for autism one severely affected 
twin had markedly smaller caudate, amygdaloid and hippocampal volume, and smaller 
cerebellar lobules compared to his brother (Kates et al. 1998). In some patients the brains 
were observed to be megalencephalic (Lotspeich and Ciaranello 1993; Bailey et al. 1998a), 
and some studies have reported slightly smaller brain volumes in autism or no difference 
compared to control groups (Rosenbloom et al. 1984; Aylward et al. 1999). A literature 
review combining autopsy material of 21 patients with autism, the brain weight of the 
patients was found to be ± 1 SD of the normal range (Courchesne et al. 1999).  
 
In brain imaging studies, abnormalities in the posterior fossa have been reported including 
hypo- and hyperplasia of the cerebellar vermal lobules (Courchesne et al. 1994; Hardan et al. 
2001) further supporting the role of the cerebellum as a modulator of mental and social 
functions (Riva and Giorgi 2000). However, in some studies no differences in these structures 
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have been detected (Holttum et al. 1992; Kleiman et al. 1992). Other abnormal findings 
include reversed left/right asymmetry of the frontal lobe (normally the left frontal lobe is 
larger than the right), enlarged lenticular nuclei and the presence of gyria malformations 
(Lotspeich and Ciaranello 1993). A recent quantitative MRI-study reported abnormal 
regulation of brain growth in autistic boys. Early overgrowth with hyperplasia in cerebral 
gray matter and cerebral and cerebellar white matter was detected in 90% of autistic boys by 
the age of two to four years, whereas in older autistic boys and adolescents the enlargement 
was not such prominent (Courchesne et al. 2001). Although not being a follow-up study, the 
authors conclude that there is abnormal growth regulation in autism leading to slowed brain 
growth (Courchesne et al. 2001).  
 
No specific marker for autism has been identified in the analyses of the blood or urine levels 
of different metabolites. Whole blood serotonin is elevated in about a quarter of autistic 
individuals as a consequence of increased amounts of serotonin in the platelets (Cook 1990), 
however no difference has been detected in the serotonin metabolite, 5-hydroxy-indoleacetic 
acid (5-HIAA) in the cerebrospinal fluid (CSF) (Narayan et al. 1993). Increased blood 
serotonin levels are also observed in other neuropsychiatric disorders, such as chronic 
schizophrenia, and mental retardation (Cook 1990). The role of serotonin in autism is 
supported by the finding that drugs inhibiting serotonin reuptake in the neurons alleviate 
aggressive behaviour and hyperactivity in patients with autism. No consistent findings of the 
studies measuring abnormalities in the dopaminergic, noradrenergic and the neuropeptide 
systems have been obtained (Bailey et al. 1996). 
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1.5. MOLECULAR GENETIC STUDIES 
 
1.5.1. Chromosomal aberrations 
 
A chromosomal aberration can be useful in localising a gene responsible for a particular 
syndrome. Autism has been associated with abnormalities of nearly every chromosome. The 
majority of them are located on the long arm of chromosome 15, which include the genes for 
Prader-Willi/Angelman syndrome and undergoes genomic imprinting, and the sex 
chromosomes (Gillberg 1998b). The most common abnormality associated with autism is 
fragile-X syndrome (Gillberg and Coleman 1996). 
 
The results of several genetic linkage studies support a susceptibility locus on the long arm of 
chromosome 7 (IMGSAC 1998; Barrett et al. 1999; Philippe et al. 1999; Risch et al. 1999; 
IMGSAC 2001b; Liu et al. 2001; Shao et al. 2002b). Also, chromosomal abberrations on this 
region, such as familial paracentric inversion in 7q and other rearrangements have been 
reported in families with autism (Ashely-Koch et al. 1999; Vincent et al. 2000; Warburton et 
al. 2000; Yan et al. 2000; Tentler et al. 2001). Mutation analyses of a gene on chromosome 
7q interrupted in a translocation t(7;13)(q31.3;q21) did not give evidence for sequence 
alterations in a group of autistic individuals (Vincent et al. 2000) 
   
1.5.2. Candidate gene studies 
 
Based on the finding of duplications on 15q11-13 in some patients with autism, association 
analyses have been conducted in order to study a putative candidate gene, -aminobutyric 
acidA receptor subunit gene (GABRB3) locating on this region. Evidence for linkage 
disequilibrium between 140 mostly singleton families with autism and 155CA-2 locating in 
the third intron of GABRB3 have been reported with P = 0.0014 (Cook et al. 1998). Also, 
positive results have been obtained on chromosome 15q11-13 in two of the genome-wide 
scans performed on autism (Barrett et al. 1999; Philippe et al. 1999). 
 
Serotonin transporter gene (5-HTT) polymorphisms, consisting of a repeat in the second 
intron, and a deletion/insertion polymorphism that regulates the expression of the transporter 
(Heils et al. 1996) have been studied in autism with contrasting results. A 
transmission/disequilibrium (TDT) analysis of 86 families with autism detected no linkage 
nor association with the polymorphism in the second intron, however a preferential 
transmission of a short variant of 5-HTT promoter (P = 0.030) was found (Cook et al. 1997). 
Klauck et al. observed transmission of the long variant in 65 singleton families (Klauck et al. 
1997). Similarly, a significant excess of the long/long 5-HTT promoter genotype was 
observed in the families as well as preferential transmission of the long allele of the 5-HTT 
promoter in a study with 33 autism families (Yirmiya et al. 2001). A further analysis did not 
show evidence for linkage nor associating of these polymorphisms (Maestrini et al. 1999). 
Also, no association have been detected between autism and the 5-HT2A receptor gene 
(Herault et al. 1996; Veenstra-VanderWeele J et al. 2002) nor between the 5-HT7 receptor 
gene or the pseudogene 5-HT7P on chromosomes 10 and 12, respectively (Lassig et al. 1999).  
 
A positive association with autism has been detected with the c-Harvey-ras-1 (HRAS1) gene, 
important in cell growth, signal transduction, cell architecture and intracellular transport 
(Herault et al. 1995; Comings et al. 1996). Also, the major histocompatibility complex on 
chromosome 6 including a null allele of the C4G gene, extended haplotype B44-SC30-DR4 
and the third hypervariable region (HVR-3) of certain DR beta 1 alleles have a strong 
association with autism (Daniels et al. 1995; Warren et al. 1996).  
 
The involvement of the HOXA1 and HOXB1 genes, critical for hindbrain development in 
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autistic individuals was studid by analysing a sequence variant in the coding region of both 
genes (Ingram et al. 2000). A significant deviation from the HOXA1 genotype ratios 
expected from Hardy-Weinberg proportions (P = 0.005) was detected in autism on 
chromosome 7p. In a more recent study no association was detected between HOXA1 or 
HOXB1 gene variants and autism in 110 multiplex families (Li et al. 2002).  
 
1.5.3. Genome-wide scans  
 
A total of eight whole genome and one autosomal genome screens have been performed in 
individuals with autism spectrum disorders (Table 4). So far, the three best overlapping 
results on autism spectrum disorders have been obtained on chromosome 2 flanking marker 
D2S2188 (Philippe et al. 1999; IMGSAC 2001b; Buxbaum et al. 2001; Shao et al. 2002b), on 
chromosome 16 at ~20-30 cM (IMGSAC 1998; Philippe et al. 1999; IMGSAC 2001b; Liu et 
al. 2001), and on chromosome 7q, although the location estimates vary (IMGSAC 1998; 
Barrett et al. 1999; Philippe et al. 1999; Risch et al. 1999; IMGSAC 2001b; Liu et al. 2001; 
Shao et al. 2002b). 
 
Table 4. A summary of the published genome screens on autism spectrum disorders. 
MMLS/het = Maximum multipoint heterogeneity lod score, NPL = nonparametric 
linkage 
REFERENCE 
 
YEAR 
 
FAMILIES ORIGIN PATIENTS BEST RESULT 
      
IMGSAC 1998 99 Caucasian, 
mostly UK 
Autism, AS and 
PDD 
Chr 7q: MLS 3.55 
(56 UK families) 
Philippe et al. 1999 51 Caucasian, 
mixed 
European 
Autism Chr 6q: MLS 2.23 
Barrett et al. 1999 75 Caucasian 
(CLSA 
families) 
Autism Chr13: MMSL/het 
3.0 
Risch et al. 1999 139 Mixed 
American 
Autism Chr1p: MLS 2.15 
Buxbaum et al. 2001 95 Not stated Autism and AS Chr2: NPL-score 
3.32 (49  families) 
Liu et al. 2001 110 Caucasian 
(AGRE 
families) 
Autism, AS and 
PDD 
Chr5: MLS 2.55 
IMGSAC 2001 83 Caucasian 
 
Autism, AS and 
PDD 
Chr2: MLS 4.0 
(strict inclusion 
criteria) 
Shao et al. 2002 99 Caucasian 
 
autism Chr X: MLS of 
2.54 
      
 
 
The first study, conducted by the International Molecular Genetic Study of Autism 
Consortium, found the best multipoint lod score (MLS) of 3.55 close to markers D7S530 and 
D7S684 in a subset of 56 UK affected sib-pair families (IMGSAC 1998). A further 
characterisation of the AUTS1 locus on chromosome 7q was recently completed on 170 
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multiplex families (IMGSAC 2001a). With the inclusion of more families and markers the 
peak of linkage (MSL of 3.37) was observed ~20 cM proximal to the initial peak at D7S477 
with 153 sib pairs fulfilling stringent inclusion criteria. This locus was designated as the first 
autism susceptibility locus, AUTS1. Interestingly, the AUTS1 locus overlaps with the 
previously identified candidate gene region for a three generation family (KE) with severe 
speech and language disorders (Fisher et al. 1998). Recently, a mutation in the forkhead-
domain gene (FOXP2) was reported in the affected members of this family (Lai et al. 2001).  
This gene encodes a putative transcription factor and a DNA-binding domain. In a recent 
study the involvement of this gene was excluded in families with developmental language 
disorder and in families with autism linked to 7q31 (Newbury et al. 2002). 
  
Liu et al. performed a genome-wide screen in autism with families belonging to the Autism 
Genetic Resource Exchange (AGRE) (Liu et al. 2001). Based on the diagnosis of the patients 
the analyses were carried out using narrow diagnostic criteria including only patients with 
autism, and broad diagnostic criteria including patients with autism, AS and PDD. On two of 
the analysed loci, evidence for increased sharing was observed with an MLS of 3.59 
combining markers D19S714 and DXS1047, with alleles in these loci tending to be 
maternally coinherited. This result suggests that a putative X-chromosomal locus may act in 
concert with an autosomal susceptibility locus/loci, explaining the increased male to female 
ratio observed in patients with autism (Skuse 2000). 
 
In 83 IMGSAC sib-pairs, thirteen candidate regions found in the primary scan (IMGSAC 
1998) were further analysed (IMGSAC 2001b). In this study patients with autism, AS and 
PDD were included. Of the previously reported 12 chromosomal regions showing MLS 
>0.82 (chromosomes 1, 2, 4, 7, 8, 9, 10, 14, 16, 17, 19 and 22) (IMGSAC 1998), only four 
regions (chromosomes 2, 7, 16 and 17) showed MLS >1.5 in the whole material (IMGSAC 
2001b). The highest MLS of 3.74 was detected at D2S2188, increasing to an MLS of 4.80 
when 127 sib-pairs fulfilling strict diagnostic criteria were studied (Table 5).  
 
In the most recent genome scan, Shao et al. performed a genome-wide scan with 52 multiplex 
families with autism (Shao et al. 2002b). Eight promising candidate regions (on 
chromosomes 2, 3, 7, 15, 18, 19 and X) were studied in a total of 99 multiplex families. The 
best two point lod scores were detected on chromosome X with an MLS of 2.54 at DXS6789. 
Interestingly the peak on chromosome 2 (MLS of 1.30 at D2S116) is located ~12 cM from 
the peak of Buxbaum et al. (Buxbaum et al. 2001). 
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 Table 5. The putative susceptibility loci for autism spectrum disorders. Only results 
with multipoint lod scores >1.5 are shown.  
LOCUS POSITION MULTIPOINT LINKAGE 
RESULT REFERENCE 
    
D1S1675 149.2 2.15 Risch et al. 1999a) 
    
D2S319 7.6 1.69 Buxbaum et al. 2001b) 
D2S2188 180.8 4.80(strict)/3.74(all) IMGSAC 2001ba) 
D2S364 186.2 2.45 Buxbaum et al. 2001 
    
D3S3680 361 1.51 Shao et al. 2002 
D3S1267 139.1 1.91 Buxbaum et al. 2001 
    
Close to D4S412 4.7 1.55 IMGSAC 1998 
    
D5S406 11.9 1.65 Buxbaum et al. 2001 
D5S2494 45-69 2.55 (B) Liu et al. 2001c) 
    
D6S309 14.1 1.65 Buxbaum et al. 2001 
D6S283-D6S261 109.2-120.3 2.23 Philippe et al. 1999 
    
D7S1813 103.6 2.2 CLSA 1999d) 
D7S477 111.8 3.37 IMGSAC 2001aa) 
D7S477 111.8 3.55(1/2)/3.20(all) IMGSAC 2001b 
D7S530-D7S684 134.5-147.2 2.53 IMGSAC 1998 
D7S495 144.7 1.66 Shao et al. 2002 
D7S483 165 2.13 (N) Liu et al. 2001 
    
D8S550 21.3 1.59 Buxbaum et al. 2001 
D8S1179 134 1.66 (B) Liu et al. 2001 
    
D9S157 32.2 3.11(1/2)/2.02(strict) IMGSAC 2001b 
D9S283 94.9 1.72 Buxbaum et al. 2001 
D9S1826 159.6 3.59(1/2)/2.23(strict) IMGSAC 2001b 
D9S158 161.7 3.16(1/2)/2.09(strict) IMGSAC 2001b 
    
D13S800 55.3 3.0 CLSA 1999 
D13S217-D13S1229  17.2- 21.5 2.3 CLSA 1999 
    
D15S129 34.1 1.49 (strict)/1.47(1/1) IMGSAC 2001b 
CYP19 40.46 2.21(1/1)/1.20(strict) IMGSAC 2001b 
    
D16S407-D16S3114 18.1-23.3 1.51 IMGSAC 1998 
D16S3102 24.5 2.93(all)/2.61(strict) IMGSAC 2001b 
D16S2619 28 1.91 (N)/1.46 (B) Liu et al. 2001 
    
5HTTINT2 45.4 2.34(all)/1.87(strict) IMGSAC 2001b 
    
D19S714 42.3 2.53(N)/1.72 (B) Liu et al. 2001 
D19S433 52 2.46 (N) Liu et al. 2001 
    
DXS6789 62.5 2.54 Shao et al. 2002 
DXS1047 –q tel 82 2.67 (N) Liu et al. 2001 
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a) Multipoint maximum lod scores (MLS) calculated by ASPEX 
b) Two-point NPL scores, only results with a P-value  0.5 are shown 
c) MLS calculated by MAPMAKER/SIBS 
d) Maximum multipoint heterogeneity lod scores (MMSL/het) 
(B) Patients with broad criteria including autism, AS and PDD 
(N) Patients with narrow criteria including only autism 
all: 152 sib-pairs 
1/2: 84 case type 1/type 2 sib-pairs 
strict: 127 case type 1/type 1 pairs + type 1/type 2 pairs 
case type 1: clinical diagnosis of autism, history of language delay and IQ≥ 35 
case type 2: clinical diagnosis of autism, atypical autism, Asperger syndrome or PDD NOS, no requirement for 
language delay 
 
 
 
Based on the excess of affected male patients observed in autism spectrum disorders the 
involvement of sex chromosomes has been studied. The X chromosome was assessed in 38 
multiplex families with autism by studying 35 microsatellite markers (Hallmayer et al. 1996). 
A moderate to strong gene effect was excluded on the whole X chromosome. Some evidence 
for linkage has been obtained in 59 multiplex families with autism on Xp (two-point 
maximum likelihood score of 0.89). A recent study in 31 families with two or more affected 
boys revealed no evidence for linkage on 16 evenly spaced X-chromosomal markers using 
the affected sib pair method (Schutz et al. 2002). Also, no similarities in Y chromosome 
haplogroups was detected in 111 autistic male patients compared to a control group (Jamain 
et al. 2002). 
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2. RETT SYNDROME 
 
2.1. CLINICAL CHARACTERISTICS AND CLASSIFICATION 
 
2.1.1. Classical Rett syndrome  
 
RTT was first described in 1966 by Andreas Rett (Rett 1966a; Rett 1966b) a paediatrician 
working in Vienna. It is the second most common genetic cause for severe mental retardation 
in girls after Down syndrome affecting 1 in 10 000 to 15 000 females worldwide (Hagberg 
1985; Skjeldal et al. 1997). The original description was largely ignored until the first English 
publication appeared in 1983 by Hagberg et al. describing 35 girls with a constellation of 
clinical features including developmental stagnation and rapid deterioration of higher brain 
functions, severe dementia, autistic features, loss of purposeful use of the hands, hand 
stereotypies, jerky truncal ataxia and acquired microcephaly (Hagberg et al. 1983). The 
diagnostic inclusion and exclusion criteria of RTT were formulated in 1988 (Table 6) (The 
Rett syndrome Diagnostic Work Group 1988). Moreover, there exist supportive criteria that 
are often present in girls with RTT including breathing dysfunction, EEG abnormalities and 
seizures, spasticity, peripheral vascular abnormalities, scoliosis, growth retardation and small, 
hypotrophic feet. Due to a lack of biological markers available at that time to support the 
diagnosis of RTT, the diagnostic criteria were formulated based on the phenotype of typical 
patients.  
 
Table 6.  
DIAGNOSTIC CRITERIA FOR CLASSICAL RTT 
 
NECESSARY CRITERIA 
 
Apparently normal pre- and perinatal development 
Developmental process within the normal range for the first 5-6 months (up to 18 months) 
Normal head circumference at birth 
Deceleration of head growth between the ages of 5 months and 4 years 
Loss of acquired purposeful hand skills between the ages 6 and 30 months, temporally 
associated with communication dysfunction and social withdrawal 
Development of severely impaired expressive and receptive language; severe psychomotor 
retardation apparent 
Stereotypic hand movements such as hand wringing/squeezing, clapping or tapping, 
mouthing and “washing” or rubbing automatisms appearing after purposeful hand skills are 
lost 
Appearance of gait apraxia and truncal apraxia/ataxia between the ages of 1 and 4 years 
Diagnosis tentative until 2 to 5 years of age 
 
EXCLUSION CRITERIA 
 
Evidence of prenatal onset of growth retardation or microcephaly 
Organomegaly or other evidence of storage disease 
Retinopathy of optic atrophy 
Existence of identifiable metabolic and other neurodegenerative disorder 
Acquired neurological disorder resulting from severe infection or trauma 
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The natural history of the classical RTT patient can be divided into four stages (Hagberg 
1993b). Stage I starts at 6-18 months of age and is characterised by growth and head growth 
slowing and early stagnation of development. Stage II which starts at 1-4 years includes rapid 
developmental regression phase including the loss of purposeful hand movements, 
vocalisation and communication, and acquisition of hand stereotypies. At this point some 
autistic features may appear. After the regression the condition stabilises in Stage III and 
slight improvement may appear. Some of the supportive criteria may become observable at 
this stage. Motor deterioration usually appears after 10 years of age in Stage IV, and is 
characterised by loss of ambulation, muscle wasting, scoliosis or kyphosis. Most RTT 
patients survive till the age of 35, although their lifespan are often shortened due to sudden 
deaths possible because of cardiac arrhythmias or brainstem dysfunction. 
 
 
2.1.2 Rett syndrome variants 
 
Increasing evidence suggested that the phenotypic variability associated with RTT is much 
wider than originally thought. Hagberg et al. have delineated six different variants with a 
presence of combination of particular symptoms (Hagberg and Gillberg 1993c; Hagberg 
1995). 
 
RTT
Early seizures
 onset
Forme fruste
Late
regression
Male
Congenital 
onset
Preserved
speech
Figure 1. RTT variants. To date no early seizure onset or late regression variants with 
MECP2 mutations have been characterised.  
 
The term forme fruste is used for variants with a milder, incomplete and protracted clinical 
course (Hagberg and Gillberg 1993c). This is the most common variant constituting 10-15% 
of the cases. The girls initially show normal development with a regression phase following 
at the age of one to three years. Hand use may be preserved and hand stereotypies are not 
necessarily present. The abnormalities necessary for RTT are usually less striking, however 
as the patients grow older the diagnosis is indisputable. 
 
 
In the course of classical RTT the patients lose their acquired speech in the regression phase 
(Stage 2). The preserved speech variants maintain the ability to speak some words or phrases 
later on, however these may appear unexpectedly and in inappropriate situations (Zappella et 
al. 1998). 
 
The variant of RTT characterised by early seizure onset includes also cases with infantile 
spasms, which may blur the clinical picture and typical signs of RTT. In the Swedish series of 
Hagberg et al. seizures at or before the age of six months were seen in 6.7% of the RTT 
patients (Hagberg and Witt-Engerström 1990). 
 
The congenital onset variant was first described by Rolando (Rolando 1985). The disease in 
this syndrome starts early on with typical RTT symptoms varying from mild to severe, and 
the necessary criteria for RTT, apparently normal psychomotor development during the first 
six months, is not fulfilled. 
 
A couple of late childhood regression variants have been described with clinical features 
resembling simple nonspecific mental retardation from early infancy to early school age. 
However, later on the probands show the typical RTT features (Hagberg and Gillberg 1993c). 
 
Males with some typical signs of the classical RTT syndrome have been characterised in the 
early 90’s, but these cases did not fulfil all the necessary criteria for RTT (Coleman 1990; 
Eeg-Olofsson et al. 1990; Philippart 1990; Topcu et al. 1991; Christen and Hanefeld 1995). 
However, typical features of RTT have been described in males with Klinefelter’s syndrome 
(47, XXY) (Vorsanova et al. 1996; Hoffbuhr et al. 2001; Leonard et al. 2001). In the few 
RTT families reported the existence of male patients with a severe form of encephalopathy 
raised the suggestions that the male RTT patients show a more severe clinical picture 
(Schanen et al. 1998). The clinical picture of these males is distinct from RTT as they are 
characterised by neonatal onset of hypotonia, seizures and apneic episodes. They developed 
microcephaly with profound developmental delay and died early at the second year of life. 
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2.2 NEUROPATHOLOGICAL AND METABOLIC STUDIES 
 
 
Before the recent discovery of the mutations in the methyl-CpG binding protein 2 (MECP2) 
gene in the majority of the RTT patients, there were no specific findings in neuropathological 
nor metabolic studies warranting the diagnosis. Some typical changes were observed in the 
majority of the patients analysed. 
 
Neuropathological and imaging studies have shown generalised brain atrophy including both 
cerebrum and cerebellum varying from ~12 to 34% in advanced RTT patients compared to 
age-matched controls (Armstrong et al. 1995). No evidence of cell loss, inflammation, gliosis 
or abnormalities in the migration pattern of neurons have been detected (Belichenko et al. 
1994).  Other morphological findings include the evidence of a decrease in neuronal cell size, 
and increased cell packing density throughout the brain (Bauman et al. 1995). These findings 
suggest that RTT is a neurodevelopmental disorder that has its greatest effects during the first 
few years of postnatal life (Hagberg and Witt-Engerström 1990) when dendritic extensions 
are increasing and synapse formation is occurring (Huttenlocher 1979). 
 
Significant changes in the three-dimensional reconstructions of dendrites and dendritic spines 
of pyramidal cell layers II and III have been reported in RTT patients (Belichenko and 
Dahlstrom 1995). The reduction of dendritic aborizations is one of the most consistent 
abnormalities associated with genetic or nonspecific mental retardation (Kaufmann and 
Moser 2000) in addition to changes in dendritic spine density and morphology. A selective 
decrease of microtubule associated protein 2 (MAP-2) immunoreactivity was observed in 
RTT in multiple brain regions, especially in the superficial white matter neurons (Kaufmann 
et al. 1995). Also, decreased immunoreactivity of MAP-2 was seen in the soma and dendrites 
of pyramidal neurons in the layers V-VI. MAP-2 is expressed early on in embryonic brain 
development and is most abundant in the microtubules (Matus 1988). The changes observed 
in RTT reflect a disturbance in the early stages of cortical maturation. The abnormalities of 
MAP-2 expression may also reflect deficits of neurotransimitters, as it is regulated 
particularly by acetylcholine, dopamine and glutamate systems (Kaufmann et al. 1995). 
 
In the neurochemical studies particular attention has been focused on the changes in 
neurotransmitters acetylcholine and dopamine. The consistent finding in the dopaminergic 
neural system in RTT is the reduction of the concentration of the intracellular neuronal 
pigment melanin in the substantia nigra (Jellinger and Seitelberger 1986). Hyperammonemia 
was detected in RTT patients in the original report by Rett (Rett 1966a), but subsequent 
studies have refuted this finding. Also, mitochondrial deficits have been suggested because of 
detectable lactatic/pyruvatic acidosis in some patients similar to mitochondrial diseases, and 
also elevated CSF lactate (Lappalainen and Riikonen 1994; Matsuishi et al. 1994; Haas et al. 
1995). However, these changes are probably secondary to apneic periods common in some 
RTT patients (Matsuishi et al. 1994). 
 
Choline acetyltransferase (ChAT) is a rate limiting enzyme for acetylicholine production, and 
is specific for cholinergic neurons. Decreased activity of ChAT has been observed in RTT in 
the basal ganglia, and also in the hippocampus and thalamus (Wenk et al. 1993; Wenk and 
Hauss-Wegrzyniak 1999). 
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2.3. MOLECULAR GENETIC STUDIES 
 
2.3.1 Identification of the MECP2 gene underlying RTT syndrome 
 
The mode of inheritance in RTT has been the subject of much debate. The disease is sporadic 
in the majority of cases and only ~0.4% represent familiar occurrences. Twin data suggests a 
full concordance rate for monozygotic twins while dizygotic twins are generally discordant 
(Zoghbi 1988).  
 
Rett syndrome was thought to be an X-linked dominant disorder lethal to males. This 
assumption was supported by the observation of a skewed X chromosome inactivation (XCI) 
pattern in phenotypically normal/mildly affected female members in one family with 
recurrence of RTT in a maternal aunt and niece (Schanen et al. 1997). The observation of a 
random XCI pattern in a phenotypically normal carrier mother in the other family with 
maternally related half-sister pairs with RTT was explained by germ-line mosaicism 
(Schanen et al. 1997). A severely affected male with encephalopathy and early death in the 
former family also favoured an X-linked inheritance pattern (Schanen et al. 1997; Schanen 
and Francke 1998). These families were used in monitoring for shared segments on the X 
chromosome and narrowing the candidate region (Archidiacono et al. 1991; Ellison et al. 
1992; Curtis et al. 1993; Schanen et al. 1997; Schanen and Francke 1998). Tentative 
exclusion mapping was performed also in full-sister pairs, but was interpreted with caution 
because of the possibility of paternal germline mosaicism for the mutation (Curtis et al. 
1993). Identification of a Brazilian family with three affected daughters with RTT enabled 
the localisation of the defective gene to Xq28. The mother was found to have a highly 
skewed XCI pattern and was thus suggested to be a carrier rather than either of the parent 
being a gonadal mosaic (Sirianni et al. 1998). Systematic sequencing of the genes located in 
the region defined by linkage analyses led to the identification of mutations in the MECP2 
gene in several RTT patients (Amir et al. 1999). 
 
2.3.2. Structure and function of the Mecp2 protein  
 
Mecp2, detected in 1992 (Lewis et al. 1992) is an abundant chromosomal protein. It is 
capable of binding to methylated CpG dinucleotides via its methyl-CpG-binding domain 
(MBD) and recruiting the histone deacetylase (HDAC) complex and corepressor Sin3A via 
its transcriptional repression domain (TRD) (Jones et al. 1998; Nan et al. 1998) (Figure 2). 
The MBD domain binds exclusively to a major groove of DNA that contains one or more 
methylated CpGs (Nan et al. 1993). In addition to specific binding to methylated DNA, 
Mecp2 also associates nonspecifically with non-methylated DNA (Meehan et al. 1992b) 
probably through short motifs that identify the minor groove of an AT-rich sequence, and are 
excluded from MBD (Meehan et al. 1992b; Nan et al. 1993). As it is a nuclear protein, 
Mecp2 contains a nuclear localisation signal (NLS) for transportation to the nucleus. The 3’-
untranslated region (3’-UTR) in exon 4 is unusually long (8.5 kb) and it is well-conserved 
between humans and mice. According to what is currently known it does not contain any 
functional domains (A. Bird, personal communication). 
 
CpG dinucleotides are concentrated on the heterochromatin regions, and promoters of human 
genes. Most of them undergo methylation of the 5-methylcytosine residues, which functions 
as an important mechanism of gene silencing associated with alterations in chromatin 
structure (Meehan et al. 1992a; Jones and Takai 2001). The epigenetic mechanism of gene 
silencing is important e.g. in X chromosome inactivation (Jeppesen and Turner 1993) and 
imprinting (Pedone et al. 1999). Gene silencing is thought to occur mainly indirectly, by 
repressor proteins that are recruited to methylated sites, although methylation alone can 
sometimes directly repress transcription (Siegfried et al. 1999). Mecp2 is capable of binding a 
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co-repressor complex consisting of the transcriptional co-repressor Sin3A and histone 
deacetylases 1 and 2 (HDAC1 and 2) via its TRD domain (Jones et al. 1998; Nan et al. 1998). 
Histone acetylation is one of the main determinants of chromatin structure, and it has been 
shown that the deacetylation or core histones renders the chromatin inaccessible to 
transcription (Eden et al. 1998). Several lines of evidence have shown that repression of 
histone deacetylation is crucial for transcriptional activation of neural specific genes during 
neuronal differentiation (Nan et al. 1998; Naruse et al. 1999; Pedone et al. 1999; Wade et al. 
1999) Mecp2 is also able to repress transcription from a distance by interacting with the 
transcriptional machinery (Nan et al. 1997; Nan et al. 1998; Kaludov and Wolffe 2000).  
 
Figure 2. Function of the Mecp2 protein in a normal individual and in a patient with 
RTT.  
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2.3.3. Mutation spectrum and clinical phenotype of the patients  
 
Since the original finding in 1999, over 20 reports have been published on the prevalence of 
the MECP2 gene mutations in RTT patients of various ethnic origins. To date, around 80 
different mutations have been characterised in the coding region of the gene. The detection 
rate in classical patients varies (30-100%), with a mean value of ~80%. The MECP2 gene is 
composed of four exons with a coding sequence of 1461 nucleotides in exons 2-4. Almost all 
mutations are sporadic due to de novo mutation of the MECP2 gene, involving CG 
transitions at CpG dinucleotides in exon 4. The majority of the mutations are nonsense 
mutations occurring mainly distal to MBD, whereas the missense mutations are concentrated 
on the MBD domain of the gene. A number of deletions of various size are found on the 3’-
end of the gene that contains palindromic and quasipalindromic sequences. In addition, 
female RTT patients with a somatic mosaicism for a deletion in the MECP2 gene have been 
described (Bourdon et al. 2001). 
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The mutations can arise mainly by two different mechanisms: 
 
- De novo, sporadic (common) 
- Parents are healthy  
- There is no family history of RTT 
- No gene mutations in the parent’s DNA 
 
-     Familial mutations (uncommon) 
- Germline mosaicism have been described (Figure 3a) 
- Mutation is inherited as an X-linked dominant trait from an obligatory 
carrier woman with a 50% risk to the offspring (Figure 3b) 
- The XCI status affects the phenotype (Figure 3b, a totally skewed XCI 
pattern protects from the disease phenotype) 
 
  
Figure 3. The familial mutations in RTT.  a) An example of germline mutation. b) The 
obligatory carrier mothers with different MECP2 mutations.  In the first example a 
totally skewed XCI pattern (100%) was observed in the carrier mother. In the second 
example the XCI status of the mother was not determined. 
 
K256X R106W 
(Amir et al. 1999; 2000) 
R168X 
(XCI: 100%)  
R168X 
R133C 
R133C 
(Wan et al. 1999; Cheadle et al. 2000)
a) b)
 
When comparing the type and the location of the mutation and the clinical phenotype several 
conclusions can be drawn. The same MECP2 mutation can result in a different clinical 
phenotype in the classical RTT patients (De Bona et al. 2000; Huppke et al. 2000; Nielsen et 
al. 2001). Cheadle et al. reported significantly milder disease in patients carrying missense 
mutations as compared with those with truncating mutations, and a milder disease was also 
associated with late rather than early truncating mutations (Cheadle et al. 2000). Similarly, 
Amano et al. found a milder disease in patients with a mutation which was located in the 
TRD domain rather than in the MBD domain (Amano et al. 2000). Amir et al. performed a 
broad correlation analysis and reported that awake respiratory dysfunction and high levels of 
CSF homovanillic acid (HVA) were more frequent in the patients with truncating mutations, 
however scoliosis was more common in patients with missense mutations (Amir et al. 2000). 
These patients with missense mutations also showed much more severe verbal abnormalities 
and more often had epileptic seizures. 
 
In addition to the classical RTT patients, MECP2 mutations have been detected in RTT 
variants (Table 7) that are similar to those in the classical patients. To date, no mutations have 
been reported for early seizure onset or late regression variants (Figure 1). 
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 Table 7. RTT variants with MECP2 mutations. 
RTT 
VARIANT 
AMINO-ACID/ 
NUCLEOTIDE CHANGE 
MUTATION 
PREVALENCE REFERENCE 
    
R255X 1/4 Orrico et al. 2000 
1162del26bp 3/3  Nielsen et al. 2001 
R133C   
Forme fruste 
T158M   
    
R133C 3/3  Huppke et al. 2000 
R168X   
P302A   
? 1/1  Amir et al. 2000 
1157del41 2/3 De Bona et al. 200 
1159del44   
R3026C 2/2 Obata et al. 2000 
R133C   
PSV 
T158M 1/2 Vacca et al. 2000 
    
Congenital 1364-1365insC 1/1 Huppke et al. 2000 
    
 
 
The spectrum of phenotype in male patients with MECP2 mutations is broad ranging from 
congenital encephalopathy and early death (Wan et al. 1999; Villard et al. 2000; Geerdink et 
al. 2002) to a severe form of MR (Meloni et al. 2000; Orrico et al. 2000; Couvert et al. 2001) 
(Table 8). Also, two studies have described two boys carrying somatic mosaicism in the 
MECP2 gene, one for P56R and the other for the R260X mutation (Clayton-Smith et al. 
2000; Topcu et al. 2002). The clinical picture of the patients represented a non-fatal 
neurodevelopmental disorder and clinical similarities to RTT.  
 
Couvert et al. reported the screening of the MECP2 gene in patients with mental retardation 
(Couvert et al. 2001). Out of 30 MR families studied, two different mutations, R168W and 
E137G, co-segregated with the disease phenotype in two different families with four and nine 
affected males respectively. In addition, four out of 185 patients found to be negative for the 
CGG expansions in the FMR1 gene which is defective in fragile-X syndrome carried a 
mutation (A140Vx2, P399L and R453Q) in the MECP2 gene. In patients with autism the 
frequent involvement of the MECP2 gene was ruled out in a group of 59 autistic patients 
(Vourc'h et al. 2001) 
 
Interestingly, MECP2 gene mutations have been detected in patients with Angelman 
syndrome (AnS), which is considered as a differential diagnosis of RTT (Imessaoudene et al. 
2001; Watson et al. 2001). AnS is mostly sporadic characterised by encephalopathy with 
microcephaly, epilepsy, absent speech, ataxia and inappropriate laughter (Williams et al. 
1995).
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 Table 8. A summary of male patients with MECP2 mutations showing atypical features of Rett syndrome. OFC = Orbito-frontal cortex. 
DATA CLAES 1997; 
MELONI. 2000 
ORRICO. 2000 YNTEMA 2001 WATSON 2001 LINDSAY 1996; 
KLAUCK 2002 
COHEN 2002 
MECP2 mutation G406X (inherited) A140V (inherited) 1161-1400del 241del2 A140V 
(inherited) 
A140V 
(inherited) 
Location of the mutation  3’-end      MBD 3’-end 5’-end MBD MBD
Familiarity 2 males (uncle and 
nephew) 
4 brothers, one 
sister, mother with 
mild MR 
A three-generation 
family (3 males, 
unaffected carrier 
female) 
No Three-generation
family with 6 
affected individuals 
 Unaffected mother 
Age of onset Infancy ? ? Neonatal Infancy 2-3 years  
Age of death 39 yrs; not yet Not yet (27-40 yrs) ? Not yet (6yrs) Not yet (>30 yrs) Not yet (12yrs) 
Growth parameters ? ? ? ? Short stature(3/6) Normal 
OFC 75th-90th in 
adulthood 
Normal in 
adulthood 
?  10th-25th 10th-90th  ? 
Severe MR + + Mild MR + Moderate, IQ~50 No 
Seizures      + ? ? + 1/6 -
Clinical findings Distal muscular 
atrophy; ataxia; 
spasticity; no 
speech; unilateral 
choreoatetosis (1 
case) 
Resting tremors; 
slow movements; 
impaired language 
development 
Nonspecific MR 
without any 
morphological or 
neurological 
features  
Dg: AnS; 
repetitive midline 
hand movements; 
tremor; muscular 
atrophy in limbs; 
ataxia 
Dg: PPM-X 
syndrome: MR, 
manic-depressive 
psychosis, 
pyramidal signs, 
parkinsonism, 
macro-orchidism 
Dg: language disorder 
and schizophrenia. 
From 12 yrs psychotic 
symptoms 
Purposeful hand skills ? ? ? ? + + 
Loss of skills +/- - ? + - During psychosis, after 
which slow recovery 
EEG  Bradyarrythmia
 
? ? Excess of slow 
wave activity 
1/6 temporally 
abnormal 
Normal 
Brain imaging Normal ? ? ? ? Normal 
Dysmorphic facial 
features 
- ? No ? No No, but bilateral 
pseudomembranous 
syndactyly of toes 2,3 
and 4 
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AnS is caused by large de novo deletions exclusively of maternal origin on 15q11-q13 
indicating that AS is caused by absence of a maternal contribution to the imprinted 15q11-
q13 region (Knoll et al. 1989; Magenis et al. 1990). Recently, mutations in the UBE3A gene 
(coding for E6-AP, a ubiquitin protein ligase) have been described in the patients. However 
in ~15% of the AnS patients no cytogenetic or molecular abnormality on chromosome 15 can 
be detected (Kishino et al. 1997; Laan et al. 1999).  
 
Imessaoudene et al. studied 78 patients diagnosed as possible AnS candidates with a normal 
methylation pattern in the UBE3A gene, and detected mutations in 4 female patients 
consistent with RTT (R106W, R255Xx2 and 803delG), one female with progressive 
encephalopathy of neonatal onset (R270X) and one male with non-progressive 
encephalopathy (G428S) (Imessaoudene et al. 2001). Recently, the G428S mutation was 
characterised to be a rare genetic variant (Laccone et al. 2002).  
 
Out of 57 patients with a diagnosis of AnS Watson et al. found an MECP2 mutation in four 
girls with similarities to RTT (1230del44, P101R, 1230del52 and Y141X) and in one male 
patient with motor delay (241del2) (Table 8).  
 
Furthermore, PPM-X syndrome characterised by psychosis, pyramidal signs and macro-
orchidism has been shown to be due to a A140V mutation in the MECP2 gene (Klauck et al. 
2002) (Table 8). Taking together, the diversity of phenotypes caused by mutations in the 
MECP2 gene is wide, and the factors affecting this variability are currently being studied. 
 
 
2.3.4. Mouse models for RTT 
 
Previous studies with Mecp2-null animals resulted in embryonic lethality, consistent with the 
idea that male patients hemizygous for the mutation would not survive (Tate et al. 1996). 
However, recently two groups generated Mecp2-null mice by using Cre-loxP cloning that 
allows the generation of spatially and temporally specific mutants that were viable (Chen et 
al. 2001; Guy et al. 2001). Guy et al. generated a deletion resulting in a protein containing 
only the eight amino-terminal amino acids, and Chen et al. a deletion with the loss of exon 3 
(Chen et al. 2001; Guy et al. 2001). The features of these mice resembled the clinical 
symptoms observed in RTT (Table 9). Also, the finding that an identical phenotype is 
observed in mice carrying CNS-specific Nestin-Cre mediated Mecp2 deletion and in Mecp2 
null mice indicate that the abnormalities observed are due to neuronal absence of Mecp2. 
Temporal Mecp2 mice mutants derived from a deletion of Mecp2 in postmitotic cells in the 
brain (CamK-Cre mediated deletion) show clinically and pathologically features which are 
similar to those of mice with Nestin-Cre mediated deletion. This result may indicate that 
Mecp2 is not indispensable for brain development, but the fact that it is needed for the 
maintenance of mature CNS neurons offers a potential opportunity for treatment in RTT 
(Chen et al. 2001). The notion that neurons are more vulnerable to Mecp2 mutation might be 
explained by a theory that neurons are more vulnerable to background transcriptional noise, 
or that Mecp2 is the primary controlling mechanism to regulate gene transcription in the 
CNS. 
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Table 9. Summary of the MECP2 null mice.  
 
 
TYPICAL FEATURES 
OBSERVED 
 
 
GUY ET AL. 2001 
 
CHEN ET AL. 2001 
   
Mecp2-null males and 
females 
No initial phenotype at birth No initial phenotype at birth 
            Age of onset  3-8 weeks of age 5 weeks of age 
            Phenotype observed Stiff, uncoordinated gait; 
reduced spontaneous 
movement; limb clasping; 
low weight/fat deposition 
(depending on the mouse 
strain); internal testes; 
uneven wearing of teeth 
Nervousness; body trembling; 
pila erection; occasional hard 
respiration, weight changes; 
physical deterioration 
            Age of death ~54 days ~10 weeks (70 days) 
            Pathological analyses  No obvious abnormalities in 
internal organs (including 
brain) 
Brain: reduced brain size and 
weight; cell bodies and nuclei 
in hippocampus, cerebral 
cortex and cerebellum were of 
smaller size (15-25%), and 
more densely packed 
   
Mecp2 deleted in the brain Similar features as in the 
Mecp2-null mice 
Similar features as in the 
Mecp2-null mice 
   
Mecp2 +/- female mice No initial phenotype at birth No initial phenotype at birth 
              Age of onset 3 months ~4 months 
              Phenotype observed Inertia; hind limb clasping; 
breathing irregularities. 
Some asymptomatic at the 
age of one year 
Weight gain; reduced activity; 
ataxic gait at later age 
               Age of death No rapid deterioration; 
long-term stability 
? 
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 3. STATISTICAL APPROACHES  
 
3.1. BACKGROUND 
 
The uncovering of the human genome consisting of 2.9 billion base pairs (bp) of DNA 
sequence has made it possible to gain a global perspective of the structure of the genome 
(Lander et al. 2001; Venter et al. 2001). The human genome project working draft sequence, 
currently over 90% complete, is fully available for the public at http://genome.ucsc.edu/. On 
the basis of the current estimates there appears to be about 30 000-40 000 proteins coding 
genes in humans, which is about twice the amount found in worm or fly.  The majority of the 
genome (75%) is intergenic DNA, and only ~1.1% of the genome constitutes of exons, the 
protein coding regions of the genes, whereas 24% is located in the introns, the sequence 
between the coding regions (Venter et al. 2001).  
 
The analysis of individual variation has been facilitated by the availability of increasing 
amounts of single nucleotide polymorphisms (SNPs) offering tools for association analyses 
and disease gene discovery. According to the current estimates there exists one SNP per 1200 
to 1500 bp nonrandomly distributed in the human genome (Venter et al. 2001). There are 
several databases that provide information on these variations (e.g. http://www.ensemble.com 
and http://www.ncbi.nlm.nih.gov/SNP/). 
  
Microsatellite markers that have widely been utilised in disease gene mapping are 2-4 bp 
repeats occurring about in every 30 kb in the genome with a typical heterozygosity of 70% 
(Weber 1990; Hearne et al. 1992). Information about several thousands microsatellite 
markers is freely available in databases such as the Genome Database 
(http://gdbwww.gdb.org/), the Whitehead Institute (http://www-genome.wi.mit.edu/), the 
Marshfield Institute  (http://research.marshfieldclinic.org/genetics/) and Généthon  
(http://www.genethon.fr/genethon_en.html). 
 
The order of the markers in genetic maps is based on the recombination fraction between two 
loci. In general, 1% recombination is equivalent to about a 106 bp of DNA (1 Mb), which is 
defined as 1 cM. However, the rate of recombination varies depending on the chromosomal 
region, the frequency of which being higher in the telomeres and short arms of the 
chromosomes, and greater in females than in males (Lander et al. 2001; Venter et al. 2001). 
The physical maps quantify the distance in terms of kilobases (1 kb of DNA equivalents to 
1000 bp).  
 
For analysis purposes the markers are amplified by polymerase chain reaction (PCR), and the 
fragments are separated by denaturing acrylamide gels. Fluorescence labels can be 
conveniently used for fragment detection. Data scanning and analysis are currently highly 
automated. 
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 3.2. LINKAGE ANALYSES 
 
The measure of genetic linkage is the recombination fraction, theta (0  0.5), which is 
defined by the frequency that a crossing over event occurs between two loci during meiosis. 
The closer the two loci are to each other the smaller is the chance for recombination. An 
estimate of  = 0.5 is consistent with the two loci being unlinked. Two traits are considered to 
be linked when they fail to be transmitted to the offspring independently from each other. In 
human Mendelian monogenic diseases tests of linkage are usually performed by the 
likelihood ratio approach also called parametric lod score analysis, which is defined by the 
following formula (Ott 1976, Morton, 1995):    
 
 
                                      L(pedigree given  = x) 
  Z(x) = log10   
     L(pedigree given  = 0.5) 
 
    
Traditionally, an odds ratio of more than 1000:1 (correspon
3) is considered as a statistically significant demonstration of
The two-point parametric lod score utilises the information o
directly additive between the families. For the calculations, c
programs have been developed, such as LINKAGE (Lathrop
1986) that uses prespecified parameters: a defined genetic m
of the disease and gene frequency.  
 
In complex diseases, linkage analyses are dependent on large
pedigrees with a given trait. In contrast to monogenic dis
complex diseases is in most cases unknown. The misspeci
lead to false positive (type -error) and false negative 
Consequently, model-independent, nonparametric linkage
developed that do not require definition of the model of inhe
(Kruglyak et al. 1996), MAPMAKER/SIBS (Kruglyak and
(Sobel and Lange 1996) programs, and SIBPAIR program f
et al. 1996).  
 
In order to map the underlying genes in complex diseases di
If relevant candidate genes are available, disease-causing m
direct sequencing of the candidate genes (Stone et al. 1997)
order to detect association (Perola et al. 1995). Alternative
loci for the disease phenotype under study a random g
analysing linkage of a trait to 300-400 polymorphic marke
(Risch and Merikangas 1996). Falsely positive associations a
by replication studies performed in different populations o
phenotype. According to Lander & Kruglyak genome-wid
distinguished from pointwise significance levels (Lander and
lod score of 3.3 (being equivalent to a P-value of 4.9x10-5) 
evidence for linkage. This higher value corresponds to a ge
5% and would compensate for the testing of multiple marker
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 L: likelihood function 
Z(x): two-point lod score in
which x presents a particular
value of  within the range
of recombination fractions. ding to a lod score of more than 
 linkage in monogenic disorders.  
f the pedigree structure and it is 
omputer based package software 
 and Lalouel 1984; Lathrop et al. 
odel of inheritance, penetrance 
 number of multiplex families or 
eases the inheritance pattern in 
fication of a genetic model may 
(type -error) linkage results. 
 analysis methods have been 
ritance, such as GENEHUNTER 
 Lander 1995) and SIMWALK 
or sib-pair analyses (Kuokkanen 
fferent strategies have been used. 
utations have been detected by 
 or analysing SNPs in a gene in 
ly, to locate new candidate gene 
enome screen is performed by 
rs evenly spaced in the genome 
nd linkage findings are excluded 
r patient material with the same 
e significance levels should be 
 Kruglyak 1995). They suggest a 
to be considered as a significant 
nome-wide false positive rate of 
s. 
 3.3. ASSOCIATION STUDIES 
 
Linkage disequilibrium (LD), the nonrandom association between alleles of linked markers is 
a powerful method for the high-resolution mapping of monogenic disorders (Hästbacka et al. 
1994). Several factors influence the level of observed LD, such as the chromosomal region 
under study, the age and mutual distance of the markers, the age and history of the population 
(genetic drift, population growth and structure, admixture or migration) (Ardlie et al. 2002). 
The younger the mutation the more extensive is the observable region of LD (Varilo et al. 
1996).  
 
The strength of association between genotype and phenotype depends on the allelic diversity 
of the disease in a given population sample. Considering the rare Mendelian disorders in the 
Finnish population, the affected individuals typically share a specific chromosomal 
haplotype, which can extend up to several cM in young populations (Varilo et al. 1996, Kere 
2001). In contrast the pattern of genetic variation underlying complex disease traits is much 
more complicated. To simplify, there exist two classes of models. The “complex trait-rare 
variant” model assumes that individually rare genetic variants that probably are population 
spesific cause the disease phenotype (Zwick 2000; Risch 2000). Being recent in origin the 
variant may be confined to a subpopulation. The other model, “complex trait-common 
variant” predicts that common disease variants are few but relatively common. These variants 
are more likely to be found globally (Zwick 2000; Risch 2000). 
 
In complex human disorders, not so promising results have been obtained on pedigree-based 
linkage analyses, and consequently whole genome based association studies have been 
suggested (Risch 2000). Association analyses with SNPs that have lower mutation frequency 
compared to microsatellite markers have now gained growing interest. So far, the studies 
have been hampered by the approximations for predicted LD between an SNP and the disease 
mutation. First approximations suggested that LD would be limited to ~3 kb (Kruglyak 
1999). However, recently published studies have shown that the extent of LD varies among 
populations, being wider in European than in African populations, and chromosomal regions 
under study (Ardlie et al. 2002, Taillon-Miller et al. 2000).  
 
Current data suggests that LD is highly structured into discrete blocks of sequence separated 
by hot spots of recombination (Daly et al. 2001; Miller and Kwok 2001; Reich et al. 2001). 
Data about the structure of the haplotype blocks demonstrate they exist in blocks of ~22 kb or 
larger in African and African-American populations and ~44 kb or larger in European and 
Asian populations (Gabriel et al. 2002). Within each block there exist only a few common 
haplotypes, which are highly correlated across populations. Taking together, the extent of LD 
useful for mapping studies has been suggested to be ~10-30 kb for northern European 
populations (Ardlie et al. 2002) requiring as many as 300 000 well-chosen SNPs for genome-
wide assocation mapping of complex diseases (Gabriel et al. 2002). 
 
Interestingly, an SNP haplotype extending over 250 kb on 5q31 region was found to confer 
an increased risk of 2.0 for Crohn disease in Canadian families. However, association 
analyses provided no means of selecting the SNP responsible for the increased risk out of the 
many SNPs uniquely associated. The at-risk haplotype extended over 250 kb (Rioux et al. 
2001). 
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 4. STRATEGIES IN COMPLEX DISEASE MAPPING 
 
 
The mapping of genetic predisposing factor(s) for common and/or complex disorders has not 
been as successful as in simple Mendelian disorders due to the multifactorial etiology of these 
diseases. The true inheritance pattern and the number of genes involved are unknown, and the 
effect of environmental factors has not been specifically characterised. The genetic 
component of a phenotype (segregating in families) is assessed by family and twin studies. 
The search for a predisposing factor begins with a careful definition of the disease phenotype 
and the collection of the family material. The different approaches besides conventional 
linkage analysis, also include studies with sib-pair material and case-control association 
studies. Genetic heterogeneity, different causes for the same phenotype, is one of the most 
important blurring factors in mapping studies. One way to simplify the phenotype is to focus 
on the most severe forms of the disease, or potential rare familial cases (Sawa and Snyder 
2002).  
 
In the characterisation of the affection status there exist several confusing factors: 
phenocopies (environmentally caused phenotype that mimics the trait under study), 
incomplete penetrance (phenotypically healthy patients carrying the mutation) and inter- or 
intrafamilial variation in the expression of the phenotype. Patients with somatic mosaicism 
carry the mutation in a certain population of cells and often express a milder form of the 
disease. As the mutation is limited to the cells present in the germline a phenotypically 
normal carrier can transmit the full disease phenotype to its offspring. Also, genomic 
imprinting (parent-of-origin differences in the gene expression) and mitochondrial 
inheritance (transmission occurs through affected females) are exceptions to the common 
vertical transmission (Haines and Pericak-Vance 1998).  
 
The utilisation of population isolates compared to outbred populations may be advantageous 
based on the reduced genetic and environmental heterogeneity due to a founder effect 
(Hovatta et al. 1999; Peltonen et al. 2000; Paunio et al. 2001; Shifman and Darvasi 2001, 
Kere 2001). However, also opposite opinions exist (Eaves et al. 2000; Jorde et al. 2000). The 
population history of Finland is characterised by a small number of initial founders, several 
bottlenecks caused by famine and war, and rapid expansion during the last 80-100 
generations that has enabled the creation of a unique genetic background (Nevanlinna 1972; 
Norio et al. 1973). Up to the 16th century only the coastline of Finland and the southeast and 
southwest areas were inhabited, the region nowadays called the early settlement or ‘old 
Finland’. Thereafter, the immigration of farmers mostly originating from a small area of 
South Savo to the inland established the late settlement region or ‘new Finland’. The 
founding population created small regional subisolates that were characterised by little 
further immigration (Kere 2001). 
 
So far, the mapping for a predisposing loci in the Finnish population has been advantageous 
e.g. in colon cancer (Peltomaki et al. 1993), diabetes (Mahtani et al. 1996), multiple sclerosis 
(Kuokkanen et al. 1997), schizophrenia (Ekelund et al. 2000) and asthma (Laitinen et al. 
2001). Similar examples of other isolated populations exist, such as mapping of 
Hirschsprung's disease in a Mennonite pedigree (Puffenberger et al. 1994), bipolar disorder 
either in a genetically isolated population of the Central Valley of Costa Rica (Freimer et al. 
1996) or in the Amish population (Ginns et al. 1996). Also, studies on schizophrenia in 
Canadian-Celtic (Brzustowicz et al. 2000) and the non-insulin-dependent diabetes mellitus in 
Mexican American and Northern European families (Horikawa et al. 2000) have resulted in 
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 promising findings. 
  
The power of isolated populations in haplotype mapping might be stronger due to long range 
LD. Populations with shorter-range LD and greater haplotype diversity may be more 
advantageous for use in the fine mapping phase. The extent of common haplotypes in the 
vicinity of predisposing loci for different complex disorders is currently under investigation. 
Potentially, a greater number of markers and larger sample size are needed for genome-wide 
association studies with outbred populations than with isolated ones (Shifman and Darvasi 
2001).  
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 AIMS OF THE PRESENT STUDY 
 
 
When this thesis was started the advances in the field of molecular genetics had made the 
mapping of complex disorders feasible. At that time the first genome-wide screens performed 
in multiplex families with autism have just been published. In order to localise the 
susceptibility genes for autism in the isolated Finnish population, we started a collaborative 
project together with skilled clinicians to collect a nationwide sample of Finnish families with 
autism spectrum disorders. During these studies, the gene responsible for RTT was identified, 
and the role of this gene was analysed in the Finnish RTT patients. 
 
 
The detailed aims were: 
 
1. To analyse the role of previously reported candidate loci for autism in the Finnish 
families with autism and AS. 
 
 
2. To localise susceptibility regions for autism spectrum disorders in the Finnish families 
using a genome-wide scan approach. 
 
 
3. To analyse the candidate regions of genome for autism spectrum disorders in families 
originating from a subisolate of Central Finland. 
   
 
4. To study the role of the MECP2 gene in Finnish classical and atypical RTT syndrome 
patients.  
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 MATERIALS AND METHODS 
 
 
5. PATIENT MATERIAL 
 
5.1. AUTISM SPECTRUM DISORDERS AND DEVELOPMENTAL DYSPHASIA  
 
The family material was obtained through a nationwide collaboration of child neurologists 
and other clinicians. Raija Vanhala, MD, Lennart von Wendt, Professor, and Taina 
Nieminen-von Wendt, MD, from Helsinki University Central Hospital, Reija Alen, MD, from 
Jyväskylä Central Hospital and Raili Riikonen, MD, and Salme Majuri, MD, from Kuopio 
University Central Hospital were the main clinical collaborators. Information about the 
research was also provided in the magazine of the Finnish association for autism and 
Asperger syndrome.  
 
Although developmental dysphasia is classified as a separate disease entity, a strong genetic 
component has also been reported in this group of disorders. Based on the coexisting 
diagnoses of autism spectrum disorders and developmental dysphasia in the same families we 
assumed that these disease entities might partly share a common genetic background. 
 
Thorough clinical and medical examinations were performed. Childhood Autism Rating 
Scale (CARS), Asperger Syndrome Screening Questionnaire (ASSQ), and Asperger´s 
Syndrome Diagnostic Interview (ASDI) (Ehlers and Gillberg 1993) were used as screening 
instruments. Also, the statements of speech therapeutics and neuropsychologists available 
were applied in the diagnosis process.  Diagnoses were carefully made by experienced child 
neurologists or paediatricians according to the DSM-IV, 4th Edition, or ICD-10 criteria 
(World Health Organization 1993). Families with associative medical conditions such as 
fragile-X syndrome, chromosomal aberrations, neurocutaneous syndromes and profound 
mental retardation were excluded. A blood sample was taken from all the available first-
degree relatives of the probands. All families were Finnish, except one father who is of 
Turkish origin.  
 
These studies have been approved by the ethical committees of the Hospital for Children and 
Adolescents of Helsinki University Central Hospital, Jyväskylä Central Hospital and National 
Public Health Institute, Helsinki. Informed written consent was obtained from the subjects 
and/or their parents. 
 
In study I, a linkage analysis of the previously reported candidate regions on autism was 
performed with 17 multiplex Finnish families consisting of 14 sibling pair core families and 
three families (Families 22, 37 and 40) with a more remote consanguinity (Table 10). 
Infantile autism was aggregating in eleven, and Asperger syndrome and autism in six 
families. The patients with developmental dysphasia were excluded from these analyses. 
 
For study II, some of the same families were analysed, and also patients confirmed to have 
developmental dysphasia were utilised. The total material consisted of 30 sib pair families, 
and eight extended families with altogether 87 affected individuals (Table 11). The family 
trees of the extended pedigrees are shown in Figure 4. For linkage analyses the patients were 
divided according to the phenotype into three diagnostic categories: infantile autism 
(criterion1; 19 families), infantile autism and AS (criterion 2; 28 families) and infantile 
autism, AS and developmental dysphasia (criterion 3; 38 families).  
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 Table 10. The family material in the exclusion mapping. Aut = autism, AS = Asperger 
syndrome, dy = dysphasia. The numbers in the brackets refer to the number (no.) of 
affected individuals with a phenotype in question. 
PHENOTYPES NO. OF 
AFFECTED FAMILIES 
TOTAL 
AFFECTED 
  Sib-pair Other Total  
      
2  7  7 14 Aut 3  2  2 6 
      
2 (1+1) 3 1 4 8 Aut+AS 3 (2+1)  1 1 3 
      
Aut+dy 3 (2+1) 1 1 2 6 
      
Aut+AS+dy 3 (1+1+1) 1  1 3 
      
 TOTAL 14 3 17 40 
      
 
Table 11. Patient material in the genome-wide scan. Aut = autism, AS = Asperger 
syndrome, dy = dysphasia. The numbers in the brackets refer to the number (no.) of 
affected individuals with a phenotype in question. 
PHENOTYPES NO. OF  
AFFECTED FAMILIES 
TOTAL 
AFFECTED 
  Sib-pair Other  Total   
      
2  13  13 26 Aut  3  1  1 3 
      
2  1  1 2 AS  3  1  1 3 
      
2 (1+1) 5 1 6 12 Aut+AS  3  (2+1)  2 2 6 
      
2 (1+1) 4 1 5 10 
3 (1+2)  1 1 3 
3 (2+1) 1 1 2 6 Aut+dy  
5 (4+1)  1 1 5 
      
Aut+AS+dy 3 (1+1+1) 1  1 3 
      
AS+dy  2 (1+1) 3 1 4 8 
      
 TOTAL 30 8 38 87 
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 In order to diminish the problem of phenotypic heterogeneity, the diagnoses of the patients 
were reassessed during the study. We paid particular attention to the classification of the 
patients with developmental dysphasia. To reduce variation when making the diagnoses the 
reassessment was performed by one specialist in child neurology. Most of the patients (11/15) 
had receptive language disorder (F80.2 according to ICD-10), which is similar to the DSM-
IV diagnosis for mixed receptive-expressive language disorder. Two out of 15 patients had an 
expressive type of dysphasia (F80.1 according to ICD-10) similar to the DSM-IV diagnosis 
for expressive language disorder, however one of them had the diagnosis of F80.2 in early 
childhood and the other was diagnosed late, the condition was first observed at the age of ten 
years. Further, one young male patient with an autistic sibling was first diagnosed to have the 
expressive type of dysphasia (F80.1), and handled as such in the analyses. Later on he 
fulfilled the criteria for autism. In one subject who was first considered to be dysphatic and 
handled as such in statistical analyses, not all the necessary diagnostic criteria for dysphasia 
or autism spectrum disorder were fulfilled. Problems in social interaction and language skills 
were observed, however, the diagnosis remained unspecified.  
 
Figure 4. The six extended families, indivuduals participating in the genome-wide scan 
are marked as dots. Black symbols = infantile autism, symbols with slashed lines = 
Asperger syndrome, and symbols with vertical lines = developmental dysphasia. 
 
Fam 39 Fam 30 Fam 40
Fam 22 Fam 66 Fam 48
 
In study III, a total of 31 core families with 48 affected individuals (37 patients with infantile 
autism and 11 patients with Asperger syndrome) originating from Central Finland were 
analysed. Autism was segregating in 23 families and AS with or without autism in eight 
families. Twenty-four of these families participated in our genome scan and 7 families are 
new. The affection status of four siblings with dysphasia and all the parents were considered 
as unknown in the analyses. In one family both parents, and in two families one of the parents 
were not available for genotyping. 
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 5.2. RETT SYNDROME  
 
Thirty-nine Finnish patients with classical RTT, and one patient with PSV participated in the 
mutation analysis of the MECP2 gene (study IV). Further 12 patients with developmental 
delay and with some RTT-like features were also included in the analyses. The diagnostic 
criteria used were as following: (I) normal pre- and perinatal development and apparently 
normal development for the first five to six months; (II) developmental regression with onset 
between six months and three years; (III) normal head circumference growth following 
deceleration between five months and four years; (IV) loss of purposeful hand movements 
and acquisition of hand movement stereotypies; and (V) marked developmental and cognitive 
delay. Altogether 52/80 (65%) of the Rett patients’ parents were available for the study: 
samples from both parents were obtained in 22 families and maternal samples alone in eight 
families. The birthplaces of the ancestors of the patients were traced back two to six 
generations (see section 6.1). 
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 6. METHODS 
 
6.1. GENEALOGICAL STUDIES  
 
Considering the history of isolation in the Finnish population genealogical studies were 
performed to locate possible founder effects in autism spectrum disorders in Finland. The 
names, dates and places of birth of the patient’s grandparents were obtained from the 
participating families. To monitor for common ancestors, Teppo Varilo, MD, performed 
genealogical analyses using population registers (Varilo et al. 1996). Church records were 
also utilised for earlier periods in the Finnish National Archives. 
 
 
6.2. DNA ISOLATION AND GENOTYPING  
 
DNA was extracted from EDTA blood according to standard procedures (Blin and Stafford 
1976). PCR reactions were performed in 15 l reaction volume containing 20 ng of genomic 
DNA, 6 pmol of both primers, 0.2 mM of dNTP, 1.5 mM MgCl2, 10 mM Tris-HCl, 50 mM 
KCl, 0.1% Triton X-100, and 0.23 U Dynazyme (Finnzymes Oy). The reactions were 
performed with the help of an MJ Research thermocycler (Cambridge, MA) using a hot-start 
procedure with Dynazyme added only after the first denaturation step of 5 min at 95ºC. The 
DNA amplification was carried out in 35 cycles as following: 30 s at 95ºC, 30 s at 
temperature specific for each primer (49-62ºC), and 30 s at 72ºC. An elongation step of 5 min 
at 72ºC terminated the reaction after the last annealing. Gel electrophoresis was performed 
using an ABI automated DNA sequencer (Applied Biosystems), and genotypes were assigned 
using the Genotype 2.0 software (Applied Biosystems) by two independent individuals. 
 
The initial genome-wide scan (study II) was performed in 19 multiplex families with 47 
affected individuals using 368 microsatellite markers from the Weber screening set 6.0 
(Sheffield et al. 1995) and 28 additional markers that were selected on the basis of the 
previously reported positive findings (Stage I). A total of 54 new markers were included to 
fine map the potential candidate regions detected in Stage I locating on chromosomes 1, 3, 7, 
9, 12, 14, 17, 19 and 21. In the fine mapping phase (Stage II), 19 additional families with 40 
affected individuals were included in the analyses (Table 11). Markers not working were 
replaced by markers from the Généthon marker map (http://www.genethon.fr/genethon_en. 
html). The fine mapping markers were selected from the maps of The Center for Medical 
Genetics (http://research.marshfieldclinic.org/genetics/) and the Genetic Location Database 
(http://cedar.genetics.soton.ac.uk/public_html/ldb.html). All the parents were genotyped, 
except in one family both parents, and in three families one of the parents were not available 
for analyses.  
 
 
6.3. LINKAGE AND ASSOCIATION ANALYSES  
 
In the linkage and association analyses the affection status of the parents without any 
phenotype was considered as unknown. 
 
In study I, two-point pairwise linkage analysis was performed in 17 families with autism and 
AS under recessive model of inheritance using the MLINK program of the LINKAGE 
package (Lathrop and Lalouel 1984; Lathrop et al. 1986). Tests of heterogeneity and 
calculations of the proportion of linked families () were performed using the HOMOG 
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 program (Ott 1986). An affecteds-only strategy was employed to minimise the effect of 
penetrance assumptions allowing no phenocopies with the disease-allele frequency set at 10-4. 
Nonparametric sib-pair analysis was performed using the SIBPAIR program (Kuokkanen et 
al. 1996). 
 
In study II, the patients with developmental dysphasia were included and three different 
liability classes were used (1 for autism, 2 for AS and 3 for developmental dysphasia). For 
statistical analyses the families were classified into three categories: families with infantile 
autism only (diagnostic criterion 1), families with infantile autism and AS (diagnostic 
criterion 2), and families with all three phenotypes (diagnostic criterion 3). Because of the 
partially overlapping diagnostic subgroups, the obtained linkage results should be cautiously 
interpreted due to the problem of multiple testing. However, taking into account that the 
evidence of linkage observed without this correction is so significant, it is probable that this 
correction does not affect the conclusions made. 
 
The maximum two point lod scores were calculated as in study I under both autosomal 
dominant and autosomal recessive modes of inheritance. On chromosomes 1 and 3q, non-
parametric maximum MLSs were calculated using the MAPMAKER/SIBS program 
(Kruglyak and Lander 1995) and parametric MLS under the dominant model of inheritance 
utilising the SIMWALK 2.81 program (Sobel and Lange 1996) in 30 sib-pair families.  
 
Association analyses were performed by calculating the P-values for TDT using the 
MENDEL 4.0 program (Lange et al. 2001) and likelihood-based haplotype relative risk 
(HRR-LRT) using the ANALYZE package. Gamete-competition analysis, as implemented in 
MENDEL 4.0 (Lange et al. 2001), was used to estimate the degree of apparent bias in the 
transmission of alleles from loci on chromosomes 1, 7 and 3q to the affected offspring 
(Sinsheimer et al. 2000). 
 
In study III, association analyses were performed with the help of TDT, gamete-competition 
analysis and association sharing test (NPL option) as implemented in MENDEL 4.0 
(Sinsheimer et al. 2000; Lange et al. 2001) on chromosomes 1, 3q and 7. In addition, a 
model-free lod score analysis in which haplotype frequencies were treated as a nuisance 
parameter was performed with PSEUDOMARKER (Goring and Terwilliger 2000), which 
uses a modified version of ILINK from the FASTLINK 4.1P package (Lathrop et al. 1984; 
Cottingham et al. 1993; Schäffer et al. 1994 and Alejandro Schäffer, personal 
communication). 
 
For genotype error elimination the PEDCHECK, MENDEL and SIMWALK 2.81 programs 
(Lange 1988, Sobel and Lange 1996; O'Connell and Weeks 1998) were utilised for study II, 
and the former one only for studies I and III. 
 
 
6.4. SEQUENCING OF THE MECP2 GENE 
 
PCR amplification of the coding exons of MECP2 was performed as described elsewhere 
(Amir et al. 1999), with slight modifications. For the 5’ portion of the exon four coding 
region a new forward primer 5’-TTCTGTACCAGGCCTGACTC-3’ was used together with 
the published reverse primer 5’-CTTCCCAGGACTTTTCTCCA-3’, at an annealing 
temperature of 60C. The PCR products were purified by treatment with 0.5 U shrimp 
alkaline phosphatase and 2.5 U exonuclease at 37C for 25 min, followed by inactivation for 
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 15 min at 80C. The purified products were sequenced directly using the ABI-PRISM dye 
terminator cycle sequencing ready reaction kit (Pelkin-Elmer) on an ABI 377 automatic 
sequencer.  Sequencing results were compared with the reference human MECP2 sequence 
(GenBank X89430 and AF030876) using a Sequencher 4.05 (GeneCodes). Both strands were 
sequenced, and all the mutations were confirmed by new reactions. The clinical picture of the 
patients (classical vs. variant RTT) was not known at the time of analysis. In cases where a 
mutation was found the parental DNA was also sequenced. All mutations were screened in a 
panel of 50 anonymous Finnish blood donors to confirm the causative function of the 
mutations. 
 
6.5. X CHROMOSOME INACTIVATION STUDIES  
 
The androgen-receptor gene polymorphism and the methylation of HpaII and HhaI sites at 
the 5’ end of the trinucleotide repeat were studied in order to identify the methylation status 
of paternal and maternal alleles (Allen et al. 1992; Pegoraro et al. 1994). DNA was extracted 
from white cell nuclei from peripheral fresh blood. Samples (1 g), were digested with 10 U 
HpaII and HhaI (Amersham Life Science) in a 25 l volume at 37C for 4 h and heat-
inactivated at 70C for 20 minutes. The PCR-amplified alleles were electrophoresed on an 
ABI 377 automatic sequencer both before and after digestion, and the peak heights were 
analysed with Genotyper v2.0 software (Perkin Elmer). Semiquantitation of the alleles was 
performed by first correcting the values for unequal amplification of alleles and then by 
calculating the average of the two separate digestions (Pegoraro et al. 1994). The values were 
rendered as a percentage, and considered skewed if they were less than 20% or higher than 
80%. 
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 RESULTS AND DISCUSSION 
 
7. MAPPING OF GENETIC LOCI FOR AUTISM SPECTRUM 
DISORDERS IN THE FINNISH POPULATION 
 
7.1. EXCLUSION OF THE PREVIOUSLY REPORTED AUTISM LOCI (I) 
 
The linkage studies with Finnish families were first concentrated on the positive regions 
previously identified in the genome-wide screens of autism (Figure 5). None of the ten 
previously reported candidate regions (on chromosomes 1p, 4p, 6q, 7q, 13q, 15q, 16p, 17q, 
19q and 22q) showed statistically significant evidence for linkage in the 17 multiplex Finnish 
families. The slightly interesting region in the analysis was on the chromosome 1p with 
markers D1S1675 and D1S534 that showed maximum lod scores of 0.87 and 0.76 
respectively (Table 12). The affected sib-pairs shared 70.5% and 60.6% of alleles IBD with 
markers D1S1675 and D1S534, respectively. These sharing proportions were roughly the 
same as the maximal IBD sharing of 65.6% near marker D1S1361 reported by Risch et al. in 
90 multiplex families (Risch et al. 1999). Multipoint analysis on chromosome 1 did not give 
any additional information in our material (data not shown). The results obtained in this study 
show that different gene loci and predisposing genes might underlie autism spectrum 
disorders in the Finnish population compared to more heterogeneous populations. However, 
taking into account the small size of our families it might be possible that we failed to 
replicate the previous findings due to the limited power of the data-set. 
 
Figure 5. Overview of the strategy of Study I. 
 
17 multiplex families with autism and AS
10 susceptibility gene loci  
37 microsatellite markers 
Two-point linkage and sib-pair analysis 
 
 
 
 
 
Table 12. Lod scores for two-point linkage analysis under the recessive model and sib-
pair analysis on chromosome 1p. Hom = Lod scores under homogeneity, Het = Lod 
scores under heterogeneity, ASP = affected sib-pair analysis, All-SP = all sib-pair 
analysis. 
 
MARKER TWO-POINT LINKAGE 
ANALYSIS 
SIB-PAIR ANALYSIS 
 Hom Het ASP All-SP 
     
D1S1631 0.06 0.06 0.01 0.02 
D1S1675 0.87 0.87 0.82 0.30 
D1S534 0.76 0.76 0.33 0.12 
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 7.2. AUTISM SUSCEPTIBILITY LOCI IN THE FINNISH POPULATION (II) 
 
7.2.1. Localisation of a major susceptibility locus, AUTS2 for Finnish families  
 
Based on the mainly negative results obtained in the analysis of the reported chromosomal 
loci for autism a genome-wide screen was performed (Figure 6). In Stage I we found nine 
chromosomal regions 1, 3p, 3q, 9, 12, 14, 17, 18 and 21, which showed a pair-wise 
parametric lod score >1 in criterion 1 families (12 families) (Table 13; Figure 7). When the 
diagnostic spectrum was broadened to include AS (criterion 2) and dysphasia (criterion 3), 
the number of families in the linkage analyses increased to 18 and 19, respectively. The 
genome regions showing some evidence for linkage (Zmax >1) for both criterion 2 and 
criterion 3 families were on chromosomes 1, 3p, 3q, 6, 19 and X. 
 
Figure 6. Schematic overview of the stages of study II. 
   
Nine best chromosomal loci for autism and the 
AUTS1 locus were fine mapped 
 
Additional 19 multiplex families with autism, 
AS and dysphasia analysed 
A total study sample of 38 families  
 
Three diagnostic criterions (1 = autism, 2 = 
autism and AS and 3 = all families) 
Genome screen with 396 microsatellite markers
 
Parametric lod score analysis under recessive 
and dominant models of inheritance 
 
19 multiplex families with autism, AS and 
dysphasia 
 
Three diagnostic criterions (1 = autism, 2 = 
autism and AS and 3 = all families) 
 
 
 
 
Stage I   
 
 
 
 
 
 
 
 
 
 
 
 
 
Stage II   
 
 
 
 
 
 
 
 
Fine mapping studies (Stage II) with additional 19 families were concentrated on the 
aforementioned loci detected with criterion 1 families. Based on the several positive findings 
on chromosome 7q region  (AUTS1 locus) (IMGSAC 1998; Barrett et al. 1999; Philippe et 
al. 1999; Risch et al. 1999; IMGSAC 2001b; Liu et al. 2001) we fine mapped this region with 
five markers.   
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 Figure 7. The Stage I susceptibility regions for autism. Lodd = dominant lod score, Lodr 
= recessive lod score 
Chr1 Chr14Chr12Chr9Chr3 Chr17 Chr18 Chr21
Lodd=1.1
Lodd=1.6
Lodd=1.9
Lodr=1.6 Lodd=1.3
Lodd=1.6
Lodr=1.4
Lodd=1.2
Lodr=1.3
 
The best results were obtained on chromosomes 1, 14 and 17 with category 1 families, on 
chromosome 3q with category 2 families and on chromosomes 3p and X with category 3 
families. 
 
Table 13. The best two-point lod scores in autism families in Stage I. Zmaxrec = recessive 
lod score, Zmaxdom = dominant lod score,  = recombination fraction,  = proportion of 
linked families. 
MARKER LOD SCORES Zmaxrec LOD SCORES Zmaxdom 
D1S1675 1.0 ( = 0.16,  = 1.0) 1.11 ( = 0.0, = 1.0) 
D3S3038 1.60 (= 0.14, = 0.64 1.67 ( = 0.0, = 0.77) 
D3S4009 1.60 ( = 0.0,  = 0.59) 0.90 ( = 0.0, = 1.0) 
D3S3554 1.64 ( = 0.1,  = 1.0) 1.90 ( = 0.0  = 1.0) 
D3S3053 1.10 ( = 0.04,  = 0.65) 0.82 ( = 0.06, = 0.92) 
D3S2427 1.45 ( = 0.16,  = 1.0) 1.77 ( = 0.0  =1.0) 
D3S2418 1.40 ( = 0.12,  = 1.0) 1.30 ( = 0.0  =1.0) 
D9S158 1.62 ( = 0.0,  =0.64) 0.87 ( = 0.08  =1.0) 
D12S2078 1.02 ( = 0.14,  =1.0) 1.30 ( = 0.0  =1.0) 
D14S297 1.53 ( = 0.1,  =1.0) 1.55 ( = 0.0  =1.0) 
D17S784 1.43 ( = 0.04,  =0.51) 1.17 ( = 0.04  =0.75) 
D18S59 1.22 ( = 0.0,  =0.40) 1.17 ( = 0.04  =0.75) 
D21S1440 1.29 ( = 0.0,  =0.44) 0.72 ( = 0.04  =0.76) 
 
 
In Stage II, supporting best evidence for linkage was observed on chromosome 3q. In this 
region, the highest two-point lod score of  Zmaxdom 	 4.31 ( = 0.0,  = 1.0) and ASP lod 
score of 4.21 (IBD sharing 82%) were observed at D3S3037 in criterion 2 families. In 
criterion 1 families the highest ASP lod score of 3.16 (IBD sharing 84%) was generated at the 
same locus. Parametric MLS analysis on the chromosome 3q region that allows for locus 
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 heterogeneity resulted in a maximum MLS of 4.81 with an -value of 1.0 in criterion 2 
families under dominant mode of inheritance (Figure 8). The maximum MLS values of 3.01 
(-value = 1.0) and 2.08 (-value = 0.65) were observed for criterion 1 and criterion 3 
families respectively at D3S3037 (Figure 8). These results suggest a susceptibility loci for a 
phenotype limited to autism spectrum (autism and AS). 
 
Figure 8. Parametric MLS on chromosome 3q in Stage II. Cat1, 2 and 3 = criterion 1, 2 
and 3 families, respectively 
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On chromosome 3q, a statistically significant TDT result was observed under criterion 1 for 
marker D3S3699 locating ~1 cM distally from D3S3037 (P-value = 0.0127) (Table 14). For 
marker D3S3730 locating close to D3S3699 evidence for association was detected with TDT 
analysis under criterion 2 (P=0.0488). The most significant evidence for association was 
generated with marker D3S3037 under criterion 2 in families originating from Central 
Finland with P = 0.0077 in TDT and P = 0.0063 in gamete competition analysis (Table 14).  
 
It is noteworthy that the highest lod scores at 3q25-27 were obtained with a broad phenotype 
including both infantile autism and Asperger syndrome suggesting that these two phenotypes 
might be caused by the same predisposing gene.  
     
Chromosome 3q locus is a novel locus that has not been found in any of the previously 
reported genome scans of autism spectrum disorders. Replication studies are needed to 
confirm whether this locus is also found in other populations or is unique to the Finnish 
population. 
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 Table 14. Chromosome 3 and 1 association and gamete-competition (GC) analyses results in Stage II. For Central Finland subset, 
families with autism and AS were analysed. HRR = haplotype relative risk analysis, TDT = transmission disequilibrium test. 
 
MARKER DIST. CRITERION 1 CRITERION 2 CRITERION 3 CENTRAL FINLAND  
 (CM) HRR-LRT TDT GC HRR-LRT TDT GC HRR-LRT TDT GC HRR-LRT TDT GC 
Chromosome 3:              
D3S2427              188.29 0.5000 0.0567 0.5649 0.5000 0.0717 0.3539 0.5000 0.1760 0.5179 0.5000 0.1582 0.3562
D3S3676             188.29 0.5000 0.3130 0.0853 0.5000 0.2550 0.0321 0.5000 0.1330 0.0660 0.5000 0.3606 0.1410
D3S3041             188.29 0.0387 0.8050 0.5676 0.0705 0.5580 0.3202 0.5000 0.2910 0.1259 0.5000 0.3532 0.3079
D3S3715              190.43 0.5000 0.4080 0.1956 0.0828 0.3140 0.2733 0.5000 0.7920 0.6542 0.4971 0.2325 0.3648
D3S3037          190.43 0.5000 0.1050 0.1330 0.5000 0.2070 0.2308 0.5000 0.4310 0.4176 0.5000 0.0077 0.0063
D3S3699             191.79 0.1252 0.0127 0.0524 0.5000 0.5370 0.4484 0.2347 0.6530 0.6709 0.5000 0.2180 0.0801
D3S3730             191.79 0.5000 0.1380 0.2834 0.3585 0.0488 0.1082 0.0952 0.0807 0.0996 0.5000 0.1900 0.2064
D3S3583              195.60 0.5000 0.6690 0.6733 0.5000 0.4850 0.4803 0.5000 0.4680 0.3546 0.5000 0.2397 0.5144
D3S2436              203.28 0.5000 0.8480 0.8816 0.5000 0.2380 0.4710 0.5000 0.1350 0.2204 0.1917 0.3716 0.7458
Chromosome 1:              
D1S1653          164.09 0.4957 0.0069 0.0231 0.5000 0.0327 0.13637 0.5000 0.1850 0.38575 0.5000 0.3710 0.2764
D1S2771          168.52 0.0020 0.0004 0.0028 0.0075 0.0006 0.13080 0.1125 0.0232 0.14521 0.0418 0.0051 0.0091
52
              
 
 
 
 7.2.2. Haplotype analysis on chromosome 3q25-27 
 
To further address the significance of the chromosome 3q25-27 region as a possible 
predisposing locus for autism in the Finnish population we constructed haplotypes in the 
analysed families and monitored for shared chromosomal segments.  
 
Haplotype analysis was performed in 17 criterion 1 families, 25 criterion 2 families and in 34 
criterion 3 families, as well as in 18 sib-pair families originating from Central Finland using 
the GENEHUNTER program. The six markers were localised on the contig map of NCBI 
(http://www.ncbi.nlm.nih.gov/). No single shared haplotype could be identified among all 
families (Figure 9). Interestingly, at marker D3S3037 allele 11 was observed in 65% of 
affected siblings originating from the Central Finland. The frequency of this allele was 24% 
in the affected siblings from the entire study material. In the normal chromosomes of the 
entire material (nontransmitted alleles of the parents) the frequency of this allele was 19%.  
 
The haplotype analysis shows an enrichment of certain alleles in the subisolate of Central 
Finland. In the -square analysis, significant results (P <0.05) were observed with markers 
D3S3037 and D3S3699 in families with autism and in families originating from Central 
Finland, respectively (Figure 9). This finding is supported by the genealogical studies 
revealing a large inbred pedigree with autism in Central Finland (see section 7.3).  
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 Figure 9. The observed chromosomal segment of ~4 cM. The P-values of the -square 
test for Category 1 and Central Finland (CF) families are shown in the bottom line. 
 Markers and contig accession number 
FAMILY D3S2427 D3S3676 D3S3041 D3S3715 D3S3037 D3S3699 
 NT_022674.3 NT_022458.4 NT_022458.4 NT_005503.4 NT_005503.4 NT_005950.5 
      
    Central Finland      
1 18 7 9 8 11 7 
2 20 6 10 8 11 7 
4 18 5 8 8 11 4 
9 20 6 10 8 10 6 
13 15 10 6 7 11 6 
19 15 6 10 8 10 0 
11 22 7 7 7 11 7 
32 22 4 8 6 11 6 
20 15 7 9 6 11 7 
14 22 9 9 6 11 6 
48 20 6 11 6 10 5 
15 20 7 8 8 10 6 
16 24 6 9 8 11 4 
51 20 9 10 8 9 6 
18 24 6 8 9 10 7 
60 19 11 9 9 11 7 
150 17 6 9 9 11 6 
      
    Outside Central Finland     
5 15 9 8 8 10 7 
6 4 0 10 7 8 4 
7 17 6 10 8 10 4 
8 21 11 10 8 11 7 
14 19 11 9 8 10 6 
10 21 6 11 8 8 6 
19 18 6 8 7 9 0 
24 20 6 4 7 6 5 
27 18 6 9 7 12 0 
28 20 9 10 6 12 7 
12 20 6 9 8 11 4 
13 4 12 6 8 12 7 
42 23 6 10 8 10 6 
17 4 9 10 6 6 0 
62 20 9 10 8 11 7 
128 19 7 8 8 9 7 
133 23 9 6 6 11 7 
       
Category 1 0.561 0.610 0.704 0.287 0.547 0.009 
CF 0.534 0.723 0.814 0.200 0.049 0.177 
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 7.2.3. Other putative susceptibility loci 
 
On chromosome 1, we obtained a Zmaxdom = 1.98 and a Zmaxdom = 2.63 at D1S1675 in 
criterion 1 and in criterion 2 families respectively. Risch et al. reported a maximum MLS = 
2.15 at the same marker in 139 sibships with mixed American origin (Risch et al. 1999). The 
results can be interpreted as a replication in this region. The data also confirms our previous 
results from the analysis of ten candidate gene regions in which the region on chromosome 
1p showed slight evidence for linkage in 17 multiplex families with autism spectrum disorder 
(study I).  Some encouraging linkage evidence emerged for the long arm of chromosome 1. 
In criterion 1 families, we found a maximum MLS = 2.63 near D1S1653 located ~13 cM 
distally from the marker D1S1675.  
 
In association analyses significant evidence for allelic association was obtained in all 
diagnostic classes for marker D1S2771 which was located ~4 cM telomerically from 
D1S1653. In TDT analysis the best P-value, 0.0004, was detected for marker D1S2771 under 
criterion 1 families (Table 14). Evidence of association in TDT was also observed for 
D1S1653 in affecteds under criterion 1 and 2 (Table 14). Interestingly, an MLS = 6.50 close 
to marker D1S1653 was recently reported in a study of schizophrenia (Brzustowicz et al. 
2000). Earlier family studies have shown increased rates of schizoid personality traits in 
families with autism (Piven et al. 1994; Piven et al. 1997a; Piven et al. 1997b; Murphy et al. 
2000), however it remains to be determined whether these neuropscyhiatric disorders share 
common susceptibility gene(s) in this particular chromosomal region. 
 
Analysis of AUTS1 locus with five markers on chromosome 7q (D7S480, D7S1804, 
D7S2437, D7S684 and D7S1824) did not give evidence for linkage (pair-wise lod scores <1) 
nor transmission disequilibrium in criterion 1 and 2 families. Interestingly, in Stage I, 
significant evidence for transmission disequilibrium was observed in criterion 3 families in 
TDT and gamete competition analysis for markers D7S2462 and D7S550 locating 8.6 cM 
apart (data not shown). Similarly, Liu et al. reported a maximum MLS = 2.13 with 110 sib-
pair families with a broad phenotype (autism, AS or PDD) at D7S483 that resides  ~4.6 cM 
proximal from our best marker D7S2462 (Liu et al. 2001). Taken together, our result gives 
further support for the localisation of a predisposing gene at 7q for a spectrum of disorders, 
broader than classical autism. 
 
In Stage II analyses no evidence for the increase of linkage could be obtained for markers on 
chromosomes 9, 12, 18 and 21.  Loci on chromosome 14q and 17q provided only suggestive 
evidence for linkage, but could still be interesting since some positive lod scores have 
previously been reported for chromosome 14 in British (IMGSAC 1998) and for chromosome 
17 in American families (Risch et al. 1999). For chromosome 17, the locus was reported in a 
mixed American sample set (Risch et al. 1999) with markers located at a significant distance, 
104 cM, proximal from our region. A Zmax = 2.19 at D17S784 was previously reported for 
familial schizophrenia (Brzustowicz et al. 2000). Thus, like in the case of chromosome 1q, 
these findings raise the possibility of shared susceptibility gene(s) underlying infantile autism 
and schizophrenia. 
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 7.3. STUDIES WITH FAMILIES ORIGINATING FROM CENTRAL FINLAND (III) 
 
Genealogical analyses of the families participating in the genome-wide scan showed that 51% 
of them have at least one grandparent born in Central Finland. More detailed analysis using 
church and population registries extending to the 18th century revealed two large pedigrees: 
one with two families having a common ancestor from Kuopio eight generations ago (Figure 
10) and the other consisting of 18 individual families with 30 affected individuals (Figure 
11). In the first pedigree, one family has three children with infantile autism and the other one 
child both with autism and severe developmental dysphasia (Figure 10). 
 
Figure 10. Two core families in the genome-wide scan with a common  ancestor. Black 
symbols = autism, symbol with vertical line = developmental dysphasia 
 
In the second large pedigree consisting of 18 
core families with autism spectrum disorders, 
the majority of the affected children have 
infantile autism whereas four families have 
Asperger syndrome. Interestingly, ancestors of 
nine families originated from the same small 
farm in the village of Rautalampi, where the 
first immigrants arrived in the 1540’s. The 
population of Rautalampi is characterised by a 
relatively small founder population, which has 
expanded to the 4100 inhabitants of today. The 
ancestors of the remaining four families have 
lived at a distance of less than 100 km from this 
core area.  
 
Given the genealogical data that shows sharing 
of same ancestors for the autism families in the 
late settlement area of Finland (Nevanlinna 
1972; Norio et al. 1973), a reasonable 
hypothesis would be that a common 
susceptibility gene underlying autism is shared 
by multiple families in this rural subisolate.    
 
 
 
 
 
To explore whether the common predisposing alleles IBD were present in the 31 families 
originating from Central Finland (including part of the large pedigree), we analysed a total of 
42 markers on the previously identified susceptibility loci, 1q and 3q, and the recently 
reported AUTS1 locus on 7q (IMGSAC 2001a) (Figure 12). 
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 Figure 12. Overview of the strategy of study III. 
 
31 multiplex families with autism and AS 
3 susceptibility gene loci  
42 microsatellite markers 
Association analyses performed 
 
 
 
 
 
 
 
 
On chromosome 3q25-27, a total of 14 microsatellite markers covering ~30 cM were 
analysed. In families with autism statistically significant results (P <0.05) with allele sharing 
statistics were observed on a 9 cM region and in families with autism and AS on a 20 cM 
region. In the former families, significant P-values for markers D3S3715 and D3S3037 were 
observed with gamete competition (0.0138 and 0.0176), TDT (0.0288 and 0.0110) and 
pseudomarker analyses (dominant: 0.0026 and 0.0076) respectively, supporting the linkage 
evidence obtained in the genome-wide scan. However, in families originating from all of 
Finland in the genome scan, no association was detected with these markers in spite of the 
linkage finding. 
 
For chromosome 1q a total of 18 microsatellite markers covering ~30 cM were studied. In 
allele sharing statistics an association was observed over an 8 cM region between markers 
D1S498 and D1S1653 in families with autism, however no haplotype was detected. The 
evidence for association was comparable to those obtained for the families from all of  
Finland. 
 
The extent of LD (8-20 cM) observed in the alleles of affected individuals emerging from a 
subpopulation of Finland with a founder effect, isolation and rapid expansion is unique and 
provides further support for the localisation of a major susceptibility locus for autism 
spectrum disorders on 3q. Whether this association reflects a true predisposing locus for 
autism or only background LD due to common genetic background shown by genealogical 
studies remains to be confirmed by larger family material and tight microsatellite and SNP 
map on this region. Previous data about monogenic disorders enriched in the late settlement 
region of Finland have shown LD that extends 8-13 cM (Peltonen et al. 1999). 
 
Presumably, a highly restricted number of genes that influence susceptibility to autism 
worldwide has been introduced into this population some 460 years ago, and became locally 
enriched. Interestingly, another complex disorder, hereditary nonpolypotic colon cancer 
(HNPCC) is also enriched in Rautalampi and results from one major mutation of the MLH1 
gene that is responsible for >50% of HNPCC in the Finnish population (Nystrom-Lahti et al. 
1994; Moisio et al. 1996).  
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 8. RETT SYNDROME (IV) 
 
8.1. THE MUTATION SPECTRUM IN FINLAND 
 
Out of 52 Finnish patients who were diagnosed as classical or atypical RTT, an MECP2 
mutation was found in all classical RTT patients (39/39; 100%) and in one PSV patient. 
However, no mutations were found in 12 patients with developmental delay and some RTT-
like features. The clinical course of the PSV patient fulfilled the diagnostic criteria for 
classical RTT in other respects apart from the longer preservation of speech. There were 
altogether 19 RTT patients with missense and 21 patients with frameshift or nonsense 
mutations that were scattered fairly evenly along the cDNA of the MECP2 gene. Eleven 
mutations (25%) were clustered in the NLS domain of 17 amino acid residues (Nan et al. 
1996). The mutational hot spot, R168X previously found in 83 RTT families was detected 
only once among this patient material. The most prevalent mutations were transitions R306C 
with six, and T158M and R255X with five occurrences (Figure 13). The PSV patient was 
found to carry a novel missense mutation P127L in the middle of the MBD region, which 
changes a conserved proline to a leucine, (Figure 13). The mutation affects the first codon of 
exon four and was not detected in the parents and in 75 normal non-RTT X chromosomes. In 
all, no mutations were detected in the parental DNA available from 52/80 (65%) of the 
parents. 
 
Figure 13. MECP2 mutations in the Finnish RTT patients.  The mutation in the PSV 
patient is shown in bold type. The exons 3 and 4 are shown in grey, the NLS domain in 
black. 
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The genealogical studies revealed one family in which two RTT patients (R3 and R5) were 
shown to be second and half-cousins. However, they carried different mutations: L386fsX403 
and G269fsX288 (Figure 14), which further supports the sporadic nature of the MECP2 
mutations in RTT. No other consanguinities could be detected even within the group carrying 
the same mutation. 
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Figure 14. The consanguineous RTT patients have different MECP2 gene mutations. 
 1878         1877 
        R5                                  R3   
 G269fsX288                  L386fsX403
8.2. XCI STUDIES  
 
Dosage compensation in humans is achieved through random inactivation of one of the two X 
chromosomes in the cells of normal females (Lyon 1989) who are essentially cellular mosaics 
with either maternal or paternal X chromosome inactivated (Lyon 1972). A skewed XCI 
pattern analysed from the peripheral cell leucocytes was reported to associate with non-
penetrant obligate carriers of the disease (Amir et al. 1999; Wan et al. 1999; Amir et al. 2000; 
Bienvenu et al. 2000), and random XCI in the patients. This led to a proposal that regardless 
of the type of mutation in the MECP2 gene, the XCI pattern would be the major determinant 
of the phenotype ranging between ratios 50/50-80/20 in the RTT patients (Schanen et al. 
1997; Sirianni et al. 1998; Wan et al. 1999). 
  
To determine whether the XCI pattern differs among the classical and atypical cases and to 
find out its contribution to the clinical phenotype, we performed XCI studies in 35 classical 
RTT, one PSV and in eight patients with RTT-like features, who were informative for the AR 
loci. All analysed cases with RTT-like features (8/12) had random XCI (Table 16). In the 25 
classical RTT patients (72%) and in the PSV patient the XCI pattern was random consistent 
with the previous reports. The methylated and subsequently inactive X chromosome was 
found in six cases of paternal origin and in one case of maternal origin.  
 
Recently, the parental origin of the MECP2 mutations was systematically studied by linkage 
analysis between the mutation of the MECP2 gene and intronic polymorphisms in 27 families 
(Trappe et al. 2001). In 26/27 families with a sporadic RTT patient the mutation was of 
paternal origin. Girard et al. found a paternal origin of the mutation in 5/7 sporadic RTT 
patients (Girard et al. 2001), and also in single familial cases the origin of the mutation is 
suggested to be in the grand paternal germline (Imessaoudene et al. 2001; Villard et al. 2001). 
These findings suggest that the excess of females in RTT is not explained by lethality of male 
embryos, but the fact that they are naturally protected from the mutations since they do not 
inherit the mutation-prone X chromosome (Thomas 1996). The explanation for the increased 
male mutation rate is not known, but it might be explained by the hypermethylated X 
chromosomes in sperm cells due to chromatin inactivation this contrasts with the oocytes 
where X chromosomes are undermethylated (Goto and Monk 1998). 
 8.3. THE CLINICAL PHENOTYPE OF THE FINNISH RTT PATIENTS 
 
8.3.1. Classical patients  
 
No significant correlation between the clinical course and mutation type was identified 
among Finnish patients with the same or different mutations (Table 15). This is in agreement 
with previous findings, although some indication for a difference in the phenotype between 
missense and truncating mutations has been reported (Amir et al. 2000; Cheadle et al. 2000; 
Huppke et al. 2000). In our patients the clinical picture associated with the R294X mutation 
was characterised by a mild clinical outcome: all learned to walk independently and if 
epilepsy was present, the seizures were infrequent. Two patients from this group (R10 and 
R42) have the best preserved gross motor skills of the entire patient material. The XCI 
pattern, which was skewed in R10 and R20 subjects carrying this mutation does not seem to 
contribute to the clinical outcome. Random XCI was also associated with two missense 
mutations (R133C and R306C), both with overall mild clinical phenotype (all patients 
learned to walk, and developed normally before regression set in at  10 months). The 
patients with nonsense mutations R255X, G269fsX288 or R270X have on the whole a more 
severe outcome than other patients. Seven out of 11 (64%) of them never learned to walk, 
compared with 5/29 (17%) of the patients with other mutations (Table 15).  
 
The relatives of RTT probands were monitored for any neurological features. The mother of 
one patient (R17) had epilepsy. However, she was not a carrier of the R270X mutation (data 
not shown). The second cousin of patient R1 presented with features from the autism 
spectrum disorders. This prompted us to investigate the whole coding region of MECP2 for 
mutations in the cousin, but no sequence alterations were detected (data not shown). The 
sister of patient R32 (DNA not available) has mild learning disabilities, and her mother 
dystony in the neck (torticollis), strabismus and myopia. However, no mutation could be 
detected in the DNA isolated from the peripheral blood of the mother (data not shown). 
 
To explain the clinical variability several reports have been published in favor of a more 
complex model consisting partly of an XCI pattern, the MECP2 mutation type and some 
modifier gene effects (De Bona et al. 2000). Healthy or mildly affected carrier females with 
random XCI patterns and A140V or G406X mutations in MECP2 gene have been reported 
(Meloni et al. 2000; Couvert et al. 2001). However, the current analysis has been limited to 
the peripheral tissue and X chromosome skewing in the CNS tissue cells cannot be excluded. 
Also, the A140V mutation has been reported in a sporadic male patient with language 
disorder and schizophrenia (Cohen et al. 2002), and in addition in patients with PPM-X 
syndrome characterised by psychosis, pyramidal signs and macro-orchidism (Klauck et al. 
2002).  
  
Our data suggest that an MECP2 mutation can be found in almost every classical Rett patient. 
Patients with a classical clinical picture without identifiable MECP2 mutation in the 
peripheral cell leucocytes may represent somatic mosacism for the mutation, as has been 
described (Bourdon et al. 2001). Alternatively, genetic heterogeneity exists, and mutations in 
other genes than in MECP2 might underlie RTT. 
 
The large number of mutations identified so far in the MECP2 gene makes the application of 
the mutation test laborious in clinical practice. However, if sequencing is considered, one 
should bear in mind that 85% (altogether 66) of all MECP2 mutations so far described are 
located in exon four (1084bp). Only twelve mutations are so far found in exon three. Two 
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 mutations involve the splicing site between exons three and four. Considering the Rett 
variants, PSV patients have often an MECP2 mutation, so far 12 cases with a mutation out of 
14 have been reported. Only one Rett patient with MECP2 mutation has been reported in the 
congenital onset group so far. More patients need to be analysed in order to clarify the 
mutation prevalence in these groups. Today no Rett variants of late regression or early onset 
seizures with a MECP2 mutation have to our knowledge been characterised. 
 
8.3.2. Atypical RTT 
 
We have screened the coding region of MECP2 in 12 patients with developmental delay and 
one or two features of Rett syndrome (Table 16) and found no mutations in this small sample. 
The patients with developmental delay had one or two features of Rett, but criteria III, partial 
or total loss of purposeful hand use, was not seen (Table 16). Similarly, patients with 
significantly milder impairment of hand use in whom an MECP2 gene mutation was not 
found have been reported (Cheadle et al. 2000). It has also been found that patients with an 
MECP2 mutation more frequently lose acquired purposeful hand movements than the 
patients without the mutation, although no significant P-value was obtained (Bienvenu et al. 
2000). 
 
All but one patient (R25) had EEG abnormalities and/or epilepsy: early onset seizures (R30, 
R39, R202), petit mal seizures (R205) and infantile spasms (R41). Scoliosis and breathing 
disorders considered as supportive criteria for Rett occurred in only 1/11 (9%) and 2/11 
(18%) of the patients, which was significantly less than in classical RTT (Table 16). In 
atypical patients R30, R39 and R202 developmental regression was associated with the onset 
of seizures. However, in RTT the regression often occurs clearly earlier than epileptic 
seizures. In patients R29 and R43 the regression was of an autistic type mainly involving the 
use of language.  
 
The spectrum of clinical features associated with an MECP2 mutation is wide ranging from 
male patients with early onset lethal encephalopathy to adult cases with severe mental 
retardation, and in female cases from asymptomatic or mild mental retardation to the severe 
variant of RTT with congenital onset (Wan et al. 1999; Meloni et al. 2000; Orrico et al. 2000; 
Couvert et al. 2001). 
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 Table 15. The MECP2 mutation, XCI status and clinical characteristics of the classical RTT patients. N.d. = no data. 
PATIENT MUTATION XCI 
(INACTIVE 
CHR.) 
YEAR 
OF 
BIRTH 
NORMAL 
DEVELOPMENT 
(M) 
WALKING 
AGE (M) 
EPILEPSY BREATHING 
DISORDER 
SCOLIOSIS SPECIAL REMARKS 
R9 R106W Noninf. -88 15 14 + + + sister has epilepsy 
R40     Random -71 <12 24 + n.d. + walked until 26 
years 
R33         P127L Random -93 12 32 + - - PSV, premature
puberty 
R24         R133C Random -95 18 18 - - - uses hands
purposefully 
R26    Random -79 24 16 + + + walked until 9-10 
years 
R47         Random -75 24 13 + + + obese
R8    T158M Random -94 12 20 - - + probably can read 
R200         100%
skewed 
-68 18 15 + + n.d.  
R37       Random -89 <12 - + + n.d. weakness in contact 
R48         Random -82 6 - + + +  
R206         Random -88 6 - + + + floppy infant
R15         R168X 85% paternal -81 12 12 + + + small and
underweight 
 
R203         Q170X Random -71 12 24 + + +  
R14          P225R Random -69 <24 15 + + + uses hands
purposefully 
R4    R255X Random -76 12 18 + + + walked until 12 
years 
R12        82% paternal -96 12 20 - + -
R13          90% skewed -67 6 - + + +
R19       Random -90 <12 - + + + weakness in contact 
R36        90% paternal -79 <12 - + n.d. n.d.  
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 PATIENT MUTATION XCI 
(INACTIVE 
CHR.) 
YEAR 
OF 
BIRTH 
NORMAL 
DEVELOPMENT 
(M) 
WALKING 
AGE (M) 
EPILEPSY BREATHING 
DISORDER 
SCOLIOSIS SPECIAL REMARKS 
R1        G269fsX28
8 
83% 
maternal 
-86 <12 - + + + mild hypotonia
R5         85% paternal -80 <12 19 + n.d. n.d.
R17 R270X Random -67 <12 - + + + mother has epilepsy 
R32          Noninf. -68 6 - + + + mother has
torticollis 
 
R38         Random -69 12 22 + + + spasticity
R44         Noninf. -86 7 - + + +  
R20 R294X 82% skewed -71 n.d. 21 + + + walked until 28 
years 
R21          Random -79 18 16 + + +
R10        90% paternal -88 12 12 + - +
R42        Random -93 24 14 - + -
R23         P302A 90% paternal -79 12 20 + + +
R11    R306C Random -81 10 21 + + + walked until 10 
years 
R22          Random -86 <24 20 + + + premature delivery
R34         Random -78 12 25 - + + still walks
R35    Random -83 18 16 + + + walked until 10 
years 
R7         Random -88 12 20 + + -
R16    Random -60 12 24 + + + walked until 20 
years 
R3         L386fsX40
3 
Noninf. -77 6 - + + +
R6         Random -91 12 18 + + +
R27  Random -85 7 - + + + brother died at 2 
months 
R46         Random -85 12 24 + + +
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Table 16. The clinical features of the atypical patients.  
PATIENT XCI YEAR 
OF 
BIRTH 
MAJOR 
CRITERIA 
MET 
WALKING 
AGE (M) 
HAND 
STEREO-
TYPIES 
EPILEPSY BREATHING 
DISORDER 
SCOL SPECIAL REMARKS 
R25   Random -98 III, V - - -, EEG 
normal 
- - MRI normal, hypotonic at birth, 
later hypertonic. 
R28  -92 V 26 + (stoking of 
hand) 
+, before 24 
mths 
- - Weak eye contact and slow 
development from birth 
R29  -94 I, II,  III,  V 12 +, flapping + - (during 
seizures) 
- Retardation and partial loss of 
speech at 24 mths, AF 
R30 Random -93 I, II,  V 12 - +, since 6 
mths 
- - Retardation and loss of speech 
at 24 mths, ataxy 
R39  -71 I, II, V - + +, infantile 
spasms since 
7 mths 
+ - Regression since infantile 
spasms 
R41  -97 III, V ? +, twisting +, since 2 
mths 
- - MRI normal, no loss of hand 
skills 
R43  -91 I, II, III, V 21 + -, EEG 
abnormalities 
- - AF, brother has unknown 
mental retardation without AF 
R45  -97 I, V - +, active 
hand use 
-, minor EEG 
abnormalities 
- ? Does not speak, febrile seizures, 
normal development till 7 mths, 
hypotonic 
R50  -62 I, V 16 -, fingers a 
robe 
+ - - AF, developmental delay since 
6 mths 
R201 Random -46       V 20 + + - + Abnormal development and 
hypotonia from birth, breast 
tumor, 
R202    15  +, since 14 
mths 
+ - Febrile seizures since 4 mths, 
autistic behaviour, dysmorphic 
features, does not speak. 
R205 Random -93 I, V 36 -, flapping 
while excited 
+,Petit mal, 
since 75 mths 
? - Hypotonic, does not speak 
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(I) normal pre- and perinatal development and apparently normal development for the first 5-6 months; (II) developmental regression with onset 
between 6 months and 3 years; (III) deceleration of head circumference growth; (IV) loss of purposeful hand movements and acquisition of hand 
movement stereotypies; and (V) marked developmental and cognitive delay. AF = autistic features; mths = months; scol = scoliosis 
 
 8.3.3. Impact on clinical practice 
 
To explain the sex-limited expression of RTT it has been suggested that the de novo 
mutations occur only in male germ cells resulting therefore in affected daughters. Males 
would be protected from the disease because they do not inherit the mutation-prone paternal 
X chromosome. Indeed, studies of the MECP2 gene mutations in sporadic cases of RTT have 
demonstrated an almost exclusive paternal origin for the mutations (Girard et al. 2001; 
Trappe et al. 2001). In all familial cases of RTT so far the mother is either a carrier or has a 
germline mosaicism for the mutation. This suggests that mutations appearing on the maternal 
alleles have a higher possibility for causing familial RTT. An analysis of the origin of the 
mutation would be beneficial for families with more than one RTT patient. This has a great 
impact on genetic counselling since the recurrence risk of a maternal germline mutation can 
be as high as 50%.  
 
Couvert et al. found an MECP2 mutation in 2/30 families with X-linked MR (Couvert et al. 
2001). In 185 sporadic mentally retarded males a mutation was detected in ~2% (4 cases) 
suggesting that the proportion of MECP2 mutations in X-linked MR is comparable with the 
3-4% rate of CGG expansions associated with fragile X syndrome. A systematic screening of 
the MECP2 gene should thus be considered in male patients with unexplained MR (Couvert 
et al. 2001).  
 
The finding of mutations in 12.5-16% of female and in 2.6-4.5% of male patients with AnS 
(Imessaoudene et al. 2001; Watson et al. 2001), indicates that the mutation analysis should be 
considered in AnS patients without a demonstrable molecular or cytogenetic abnormality of 
15q11-13 (Watson et al. 2001). In the families where AnS is diagnosed on clinical grounds 
only, the recurrence risk can be as high as 50%, however if an MECP2 mutation was detected 
in the proband this risk would be much lower. Also, screening should be indicated for 
females not fulfilling the classical diagnostic criteria for RTT who show delayed motor 
development regardless of age, and in patients with PPM-X syndrome. 
 
Before an MECP2 sequence variation is considered to be disease causing in male patients, the 
analysis of parental and grandparental DNA was recently strongly emphasised (Laccone et al. 
2002). Also, the frequency of the variation should be studied in a suitable population. Indeed, 
Laccone et al. showed that an MECP2 gene mutation (G428S), previously described to be 
responsible for the disease phenotype in a male patient, is actually a rare genetic variant. 
They suggested that the novel amino acid changes reported should be defined as 
“unclassified” until they are definitely confirmed as disease causing mutations (Laccone et al. 
2002). 
 
The current guidelines for MECP2 mutation screening is advised in girls with developmental 
delay, hypotonia, tremulous movement, poor feeding, poor mobility, fall-off in the growth of 
the head circumference and onset of epileptic seizures or nonepileptic vacant spells (Kerr et 
al. 2001). Also the screening of infants fulfilling at least five of the necessary diagnostic 
criteria for RTT has been recommended (Inui et al. 2001).  
 
Finally, the role of MECP2 mutations in developmental delay of male patients needs further 
studies and careful characterisation of the affected patients before screening criteria can be 
formulated. 
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 CONCLUSIONS 
 
 
Molecular genetic studies performed to date on autism spectrum disorders have resulted in 
the identification of numerous genetic loci. Of the positive findings the chromosome 2q and 
7q loci have been repeatedly found in independent family materials. The majority of the 
studies have been performed in families with infantile autism only. In this study it has 
become increasingly evident that the phenotypic spectrum in families with autism is wider 
including siblings not only with Asperger syndrome but also developmental language 
disorders currently classified as a separate disease entity. Also others have reported positive 
linkage findings in patients belonging to the autism spectrum (IMGSAC 1998; IMGSAC 
2001a; Buxbaum et al. 2001; Liu et al. 2001), however developmental dysphasia has not been 
included in these studies.  
 
The above findings reflect the inadequacy of our understanding of the phenotypic diversity in 
neuropsychiatric disorders. Currently, the diagnosis, which depends only on a certain 
behavioural phenotype as no biochemical markers are available, contains the risk for 
phenotypic heterogeneity. Development of new diagnostic instruments is needed to 
distinguish between various endophenotypes within similar genetic backgrounds in the 
affected children  and their family members (Shao et al. 2002a). The failure to replicate the 
previous positive linkage findings may also be explained by different ethnicity, inadequate 
statistical approaches used or by the relatively small family material.  New statistical methods 
have already been developed for quantitative trait analysis and models for several interacting 
genes (Daniels et al. 1996; Liu et al. 2001). Development of statistical methods in this field 
will further help us to understand the interaction between disease traits and environmental 
factors. 
 
A novel locus for autism spectrum disorders, AUTS2, was found on chromosome 3q25-27 
with a strong allelic association in the Finnish families. The region of significant LD was 
even larger in families originating from a subisolate of Central Finland. Whether these results 
reflect a closely locating trait for autism spectrum disorders or only background LD due to 
the isolation needs further studies. Indeed, significant background LD was detected in a 
subisolate of Sardinia in two regions of the X chromosome (Zavattari et al. 2000). The role of 
founder populations in the mapping of genes for complex disease traits has not yet been 
established. However, the unique population history may have enriched rare mutations 
specific to certain consanguineous families. It might also be easier to identify the 
environmental factors in these families who originate from the same rural area once the 
predisposing gene alterations have been identified. The localisation of a putative disease-
predisposing variation for autism spectrum disorders on chromosome 3q will be further 
studied by concentrating on the families originating from the subisolate. Additional 
association studies will be performed with the help of non-autistic control group from this 
particular region of Finland. 
 
The increasing amount of the human genome sequence data will add to our knowledge about 
new candidate genes for autism spectrum disorders. Furthermore, the increasing number of 
SNPs, currently over 4 million found (Gabriel et al. 2002), will facilitate the construction of 
haplotypes in different chromosomal regions and different populations. The data about 
background haplotype structures will help in utilising LD-mapping to evaluate the association 
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 of a genetic marker and a disease trait.  Also, it will help to sort out which type of populations 
would be ideal for the identification of complex disease traits. 
 
Rett syndrome was the first human disease characterised by mutations in an X-linked gene 
involved in DNA methylation. Recently, at least 20 genes with causative mutations have been 
detected for syndromes with severe MR on X chromosome, some of which are also involved 
in chromatin remodelling (Chelly and Mandel 2001). The gene defective in RTT, MECP2, 
belongs to a gene family with a functional MBD-domain and abilities to repress transcription 
(Hendrich and Bird 1998). The MECP2 gene undergoes X chromosome inactivation, and 
consequently the affected patients are functionally mosaics of the MECP2 gene that is 
expressed ubiquitously in humans. However, on the basis of the mouse models loss of 
function only in the central nervous system is enough to cause the disease symptoms (Chen et 
al. 2001; Guy et al. 2001). The cell environment in neurons most probably demands tightly 
controlled genomic methylation (Tucker 2001). The genes silenced by MECP2 gene and the 
pathogenetic mechanisms leading to the alterations observed –shrunken brain size and loss of 
tissue morphology and structure– are currently being studied. 
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